

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064595 A1

(51) International Patent Classification⁷: C07D 487/04,
A61K 31/519

(21) International Application Number: PCT/EP02/01961

(22) International Filing Date: 11 February 2002 (11.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,757 14 February 2001 (14.02.2001) US

(71) Applicant (for all designated States except US):
WARNER-LAMBERT COMPANY [US/US]; 201
Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDRIANJARA,
Charles [FR/FR]; 3, rue Auguste Daix, F-94260 Fresnes
(FR). JACOBELLI, Henry [FR/FR]; 65, avenue du
Général de Gaulle, F-91550 Paray Vieille Poste (FR).
GAUDILLIERE, Bernard [FR/FR]; 28, rue de Zilina,
F-92000 Nanterre (FR). BREUZARD, Francine [FR/FR];
42, rue Fontaine Cornaille, F-91480 Quincy sous Senart
(FR).

(74) Agents: HIRSCH, Denise et al.; Pfizer, Global Research
and Development, Fresnes Laboratories, 3-9, rue de la
Loge, B.P. 100, F-94265 Fresnes Cedex (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,

[Continued on next page]

(54) Title: TRIAZOLO COMPOUNDS AS MMP INHIBITORS



(57) Abstract: A compound selected from those of
formula (I): in which: W represents N or C-R₁; in
which R₁ is as defined in the description, X represents
N or C-R₂ in which R₂ is as defined in the description,
Y represents a group selected from oxygen, sulfur,
-NH, and -Nalkyl, Z represents a group selected from
oxygen, sulphur, -NR₈ in which R₈ is as defined in
the description, and optionally carbon depending the
definition of Y, n is an integer from 0 to 8 inclusive,
Z₁ represents a group -CR₉R₁₀ wherein R₉ and R₁₀

are as defined in the description, which group contains optionally multiple bonds or heteroatoms, A represents a cyclic group, m is
an integer from 0 to 7 inclusive, the group(s) R₄ is (are) as defined in the description, R₃ represents a group selected from hydrogen,
alkyl, alkenyl, alkynyl, and the group of formula (II): in which p, Z₂, B, q, and R₁₃ are as defined in the description, optionally, its
racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof, and medicinal products
containing the same are useful as specific inhibitors of tpe-13 matrix metalloprotease.



TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent
(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Triazolo compounds as MMP inhibitors

Field of the invention

The present invention relates to novel cyclized quinazolines which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor. These medicinal products are useful in particular
5 for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.

Technological background of the invention

Matrix metalloproteases (MMPs) are enzymes which are involved in the renewal of extracellular matrix tissue, such as cartilage, tendons and joints. MMPs bring about the
10 destruction of the extracellular matrix tissue, which is compensated for, in a non-pathological physiological state, by its simultaneous regeneration.

Under normal physiological conditions, the activity of these extremely aggressive peptidases is controlled by specialized proteins which inhibit MMPs, such as the tissue inhibitors of metalloprotease (TIMPs).

15 In pathological situations, an irreversible degradation of articular cartilage takes place, as is the case in rheumatic diseases such as rheumatoid arthritis or osteoarthritis. In these pathologies, the cartilage degradation process predominates, leading to a destruction of the tissue and resulting in a loss of function.

At least twenty different matrix metalloproteases have been identified to date and
20 are subdivided into four groups, the collagenases, the gelatinases, the stromelysins and the membrane-type MMPs (MT-MMPs), respectively.

Matrix metalloprotease-13 (MMP-13) is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.

25 Local equilibrium of the activities of MMPs and TIMPs is critical for the renewal of the extracellular matrix. Modifications of this equilibrium which result in an excess of

active MMPs, relative to their inhibitor, induce a pathological destruction of cartilage, which is observed in particular in rheumatoid arthritis and in osteoarthritis.


There is a need in the prior art for novel MMP inhibitors, more particularly for MMP-13 inhibitors, in order to prevent and/or correct the imbalance in the renewal of extracellular matrix tissue, as well as to prevent or treat conditions such as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPDs), age-related macular degeneration (ARMD) and cancer.

MMP-inhibitor compounds are known. Most of these MMP inhibitors are not selective for only one MMP, such as, for example, those which have been described by Montana and Baxter (2000) or by Clark et al. (2000).

There is a need in the prior art for novel inhibitors that are active on matrix metalloprotease-13 in order to enrich the therapeutic arsenal that can be used for treating pathologies associated with the destruction of the extracellular matrix and with cancer.

SUMMARY OF THE INVENTION

The invention relates to cyclized quinazolines of formula (I)



in which:

W represents N or C-R₁; in which R₁ is selected from:

- hydrogen atom,
- OR₅, SR₅ in which R₅ is selected from hydrogen, (C₁-C₆)alkyl and aryl(C₁-C₆)alkyl,
- (C₁-C₆)alkyl, cycloalkyl of 3 to 8 carbon atoms optionally interrupted with one hetero atom selected from oxygen, sulfur and nitrogen, aryl, heteroaryl and aryl(C₁-C₆)alkyl, these groups being optionally substituted by (CH₂)_p-OH or (CH₂)_p-NH₂, in which p is an integer from 0 to 4 inclusive.

X represents N or C-R₂ in which R₂ is selected from:

- hydrogen atom,
- NR₆R₇, OR₆, SR₆ in which R₆ and R₇, identical or different, are selected from hydrogen, (C₁-C₆)alkyl and aryl(C₁-C₆)alkyl,
- 5 • (C₁-C₆)alkyl, cycloalkyl of 3 to 8 carbon atoms optionally interrupted with one hetero atom selected from oxygen, sulfur and nitrogen, aryl, heteroaryl and aryl(C₁-C₆)alkyl, these groups being optionally substituted by (CH₂)_p-OH or (CH₂)_p-NH₂, in which p is an integer from 0 to 4 inclusive,

Y represents a group selected from oxygen, sulfur, -NH, and -N(C₁-C₆)alkyl,

10 Z represents a group selected from:

- oxygen, sulphur,
- and -NR₈ in which R₈ represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl(C₁-C₆)alkyl, cycloalkyl, aryl, and heteroaryl, and
- when Y is oxygen, sulphur, or -N(C₁-C₆)alkyl, Z optionally represents a carbon atom
- 15 which is optionally substituted by a group selected from (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl,

n is an integer from 0 to 8 inclusive,

Z₁ represents a group -CR₉R₁₀ wherein R₉ and R₁₀, identical or different, represent a group selected from hydrogen, (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halogen, NR₅R₁₁, OR₅, SR₅ and

20 C(=O)OR₅ in which R₅ and R₁₁, identical or different, represents hydrogen atom or (C₁-C₆)alkyl, and

- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one or more multiple bonds,
- and/or one of the carbon atoms in the hydrocarbon chain Z₁ may be replaced with an
- 25 oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,

A represents a group selected from :

- aromatic or non-aromatic, 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, and
- bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

m is an integer from 0 to 7 inclusive,

the group(s) R₄, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -NO₂, -SCF₃, -CF₃, -OCF₃, -NR₅R₁₁, -OR₅, -SR₅, -SOR₅, -SO₂R₅, -(CH₂)_kSO₂NR₅R₁₁, -X₁(CH₂)_kC(=O)OR₅, -(CH₂)_kC(=O)OR₅, -X₁(CH₂)_kC(=O)NR₅R₁₁, -(CH₂)_kC(=O)NR₅R₁₁, and -X₂-R₁₂ in which:

- X₁ represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by hydrogen or (C₁-C₆)alkyl,

- k is an integer from 0 to 3 inclusive,


- R₅ and R₁₁, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

- X₂ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,

- R₁₂ represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxyl, and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

R₃ represents a group selected from:

- hydrogen,
- (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, these groups being optionally substituted by one or more groups, which may be identical or different, selected from amino, cyano, halo(C₁-C₆)alkyl, cycloalkyl, -C(=O)NR₅R₁₁, -C(=O)OR₅, -OR₅, and -SR₅, in which R₅ and R₁₁, which may be identical or different, are as defined hereinbefore,
- and the group of formula :



✓ in which p is an integer from 0 to 8 inclusive,

✓ Z₂ represents -CR₁₄R₁₅ wherein R₁₄ and R₁₅, identical or different, represent a group selected from hydrogen, (C₁-C₆)alkyl, phenyl, halo(C₁-C₆)alkyl, halogen, amino, -OR₅, -NR₅R₁₁, -SR₅ and -C(=O)OR₅ in which R₅ and R₁₁, identical or different, are as defined hereinbefore, and

- when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one or more multiple bonds,
- and/or one of the carbon atoms in the hydrocarbon chain Z₂ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,

✓ B represents a group selected from:

- aromatic or non-aromatic 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, and
- bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,


✓ q is an integer from 0 to 7 inclusive,

- ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-NO_2$, $-CF_3$, $-OCF_3$, (C_1-C_6) acyl, $-(CH_2)_kNR_{16}R_{17}$, $-X_3-(CH_2)_kNR_{16}R_{17}$, $-N(R_{16})C(=O)R_{17}$, $-N(R_{16})C(=O)OR_{17}$, $-N(R_{16})SO_2R_{17}$, $-N(SO_2R_{16})_2$, $-OR_{16}$, $-S(O)_{k_1}R_{16}$, $-(CH_2)_kSO_2NR_{16}R_{17}$, $-X_3(CH_2)_kC(=O)OR_{16}$, $-(CH_2)_kC(=O)OR_{16}$, $-X_3(CH_2)_kC(=O)NR_{16}R_{17}$, $-(CH_2)_kC(=O)NR_{16}R_{17}$, $-C(=O)O-R_{19}-NR_{16}NR_{17}$ and $-X_4-R_{18}$, in which :
- X_3 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by a hydrogen atom or a (C_1-C_6) alkyl group,
 - k is an integer from 0 to 3 inclusive,
 - k_1 is an integer from 0 to 2 inclusive,
 - R_{16} and R_{17} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
 - X_4 represents a group selected from single bond, $-CH_2-$, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C_1-C_6) alkyl group,
 - R_{18} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring, which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl, (C_1-C_6) alkoxy, oxo, cyano, tetrazole, $-NR_5R_{11}$, and $-C(=O)OR_5$ wherein R_5 and R_{11} are as defined hereinbefore, and, when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
 - R_{19} represents a (C_1-C_6) alkylene group,
- optionally, the racemic forms, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof.

The compounds of the present invention are useful as inhibitors, in particular as selective inhibitors, of the enzyme matrix metalloprotease-13 (MMP-13).


The invention also relates to a process for manufacturing the compound of formula (I) in which W , X , R_3 , R_4 , n , m , Z_1 and A are as defined above, Y is O and Z is O , the said

process being characterized in that it comprises the reaction of the compound of formula (7a):




in which W, X, and R₃ are as defined in the compound of formula (I),

5 with the compound of general formula (7g), in the presence of a base:




in which hal is a halogen atom such as chlorine or bromine, and in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),

10 to give the compound of general formula (7c), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

A subject of the present invention is also a process for manufacturing a compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is -NR₈, the said process being characterized in that it comprises the reaction of the compound of formula (7a):




in which W, X, and R₃ are as defined in the compound of formula (I),
with the compound of general formula (7i) :



in which R₄, R₈, n, m, Z₁ and A are as defined in the compound of formula (I),


5 by activating the acid function with an activator such as O-
[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate
(TOTU), in the presence of diisopropylethylamine (DIPEA) in a solvent such as
dimethylformamide (DMF), to give the compound of general formula (7d), which is a
particular case of the compounds of formula (I):



10


in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.

A subject of the present invention is also a process for manufacturing a compound of
formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is S,
the said process being characterized in that it comprises the reaction of the compound of
15 formula (7a):




in which W, X, and R₃ are as defined in the compound of formula (I)

with the compound of general formula (7j)




in which R_4 , n , m , Z_1 and A are as defined in the compound of formula (I),

by activating the acid function with an activator such as TOTU, in the presence of DIPEA in a solvent such as DMF, to give the compound of general formula (7e), which is a particular case of the compounds of formula (I):




in which W , X , R_3 , R_4 , n , m , Z_1 and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W , X , R_3 , R_4 , n , m , Z_1 and A are as defined above, Y is O and Z is O , the said process being characterized in that it comprises the reaction of the compound of formula (7b):



in which W , X , and R_3 are as defined in the compound of formula (I),


with the compound of formula (7h):



in which R_4 , n , m , Z_1 and A are as defined in the compound of formula (I),


in the presence of a base such as triethylamine (TEA), to give the compound of general formula (7c), which is a particular case of the compounds of formula (I):

10




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is -NR₈, the said process being characterized in that it comprises the reaction of the compound of formula (7b):




in which W, X, and R₃ are as defined in the compound of formula (I),

with the compound of formula (7i):




in which R₄, R₈, n, m, Z₁ and A are as defined in the compound of formula (I),

in the presence of a base such as TEA, to give the compound of general formula (7d), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is S, the said process being characterized in that it comprises the reaction of the compound of formula (7b):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7j):



in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),


10 to give the compound of general formula (7e), which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.


15 The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is -CHRa, in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, the said process being characterized in that it comprises the reaction of the compound of formula (7b):

12




in which W, X, and R₃ are as defined in the compound of formula (I),

with the compound of general formula (7k):




in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, Hal represents a halogen atom, and R₄, n, m, Z₁ and A are as defined in the compound of formula (I),

to give the compound of general formula (7f), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, Ra, n, m, Z₁ and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined in the summary of the invention and Y is S, the said process being characterized in that it comprises the reaction of the compound (8a), which represents all the compounds of formulae (7c), (7d), (7e), and (7f):




in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined in the compound of formula (I), with Lawesson's reagent or P₂S₅, to give the compound of general formula (8b), which is a particular case of the compounds of formula (I):




5 in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is NH and Z is O, the said process being characterized in that it comprises the reaction of compound (9a):




10

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7h):




in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),

15 to give the compound of general formula (9b), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in the summary of the invention, Z is -NR₈ and Y is NH, the said process being characterized in that it comprises the reaction of compound (9a):




in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7i):



in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),


to give the compound of general formula (9c), which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.


The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in the summary of the invention, Z is S and Y is NH, the said process being characterized in that it comprises the reaction of compound (9a):

15




in which W, X, and R₃ are as defined in the compound of formula (I)

with the compound of general formula (7j):



5 in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),


to give the compound of general formula (9d) which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.


10 The invention also relates to a process for manufacturing the compound of formula (I) in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in the summary of the invention, Z is -CHRa in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, and Y is N-Rb in which Rb is a (C₁-C₆)alkyl, the said process being characterized in that it

15 comprises the reaction of compound (7f):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in the compound of formula (I), and in which R_a is as defined hereinbefore,

with R_b-NH₂, in which R_b represents a (C₁-C₆)alkyl group, in a presence of a dehydrating agent, to give the compound of general formula (10a), which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁, R_a, R_b and A are as defined hereinbefore.

The invention also relates to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable excipient.


The invention also relates to the use of a compound of formula (I) for the preparation of a medicinal product intended for treating a disease or complaint involving therapy by inhibition of matrix metalloproteases, and more particularly of MMP-13, such as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPDs), age-related macular degeneration (ARMD) and cancer.

The invention also relates to a method for treating a disease or complaint involving a therapy by inhibition of matrix metalloproteases, and more particularly of MMP-13, the said method comprising the administration of an effective concentration of a compound of formula (I) to a patient.

DETAILED DESCRIPTION OF THE INVENTION

The Applicant has identified according to the invention novel compounds that are matrix metalloprotease inhibitors, and more specifically novel compounds that are MMP-13 inhibitors.

The subject of the invention is thus cyclized quinazolines of formula (I):



5

in which W, X, Y, Z, R₃, R₄, n, m, Z₁ and A are as defined in the summary of the invention, optionally the racemic forms, isomers thereof, N-oxydes thereof, as well as the pharmaceutically acceptable salts thereof.

The invention relates particularly to the compounds of general formula (I) in which:

10

W is C-R₁ and X is N or C-R₂ in which R₁ and R₂, identical or different, are selected from hydrogen and methyl,

Y is O,

Z represents an oxygen atom or -NH group,

15

n is an integer from 0 to 4 inclusive,

Z₁ represents a group -CR₉R₁₀ wherein R₉ and R₁₀, identical or different, represent a group selected from hydrogen, (C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halogen, -NR₅R₁₁, -OR₅, -SR₅ and -C(=O)OR₅ in which R₅ and R₁₁, identical or different, represent hydrogen atom or (C₁-C₆)alkyl, and

20

- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one double bonds,

- and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

R_3 , R_4 and A are as defined in the compound of formula (I).

- 5 The invention also relates to the compounds of general formula (I) in which R_3 represents the group of formula:



- ✓ in which p is an integer from 0 to 4 inclusive,
- ✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen and methyl, and when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one double bond,
- ✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,
- 15 ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, -CN, -CF₃, -NR₁₆R₁₇, -OR₁₆, -SO₂R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -O(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -O(CH₂)_kC(=O)NR₁₆R₁₇, -C(=O)O-R₁₉-NR₁₆NR₁₇ and -(CH₂)_kC(=O)NR₁₆R₁₇, in which k is an integer from 0 to 3 inclusive, R_{16} and R_{17} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl, and R_{19} represents a (C_1-C_6) alkylene group,
- 20 W, X, Y, Z, Z_1 , n, m, A and R_4 are as defined in the compound of formula (I).

The invention also relates to the compounds of general formula (I) in which:

n is an integer from 0 to 4 inclusive,

Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} represent each hydrogen atom, and

- when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one double bond,
- and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

- 10 m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_5R_{11}$, $-OR_5$, and $-C(=O)OR_5$ in which R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,

W , X , Y , Z and R_3 are as defined in the compound of formula (I).

15

The invention relates more particularly to a cyclized quinazoline of general formula (I) in which:

W is $C-R_1$ and X is N or $C-R_2$ in which R_1 and R_2 , identical or different, are selected from hydrogen and methyl,

- 20 Y is O ,

Z represents an oxygen atom or $-NH$ group,

n is an integer from 0 to 4 inclusive,

Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , identical or different, represent a group selected from hydrogen and methyl, and

- when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one or more multiple bonds,
- 5 • and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, 10 benzofurazanyl, and indolyl,

m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_5R_{11}$, $-OR_5$, $-SO_2R_5$, $-(CH_2)_kSO_2NR_5R_{11}$, $-X_1(CH_2)_kC(=O)OR_5$, $-(CH_2)_kC(=O)OR_5$, $-X_1(CH_2)_kC(=O)NR_5R_{11}$, $-(CH_2)_kC(=O)NR_5R_{11}$, and $-X_2-R_{12}$ in which:

- 15 ✓ X_1 represents a group selected from oxygen, sulphur and $-NH$,
- ✓ k is an integer from 0 to 3 inclusive,
- ✓ R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
- ✓ X_2 represents a group selected from single bond, $-CH_2-$, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
- 20 ✓ R_{12} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl and amino, and
- 25 when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

R₃ represents the group of formula:



- ✓ in which p is an integer from 0 to 6 inclusive,
- 5 ✓ Z₂ represents -CR₁₄R₁₅ wherein R₁₄ and R₁₅, identical or different, represent a group selected from hydrogen, (C₁-C₆)alkyl, phenyl, halo(C₁-C₆)alkyl, halogen, amino, OR₅, SR₅ and -C(=O)OR₅ in which R₅ is as defined in the compound of formula (I), and
 - when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one or more multiple bonds,
 - 10 • and/or one of the carbon atoms in the hydrocarbon chain Z₂ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,
- ✓ B represents a group selected from:
 - aromatic or non-aromatic 5- or 6-membered monocycle comprising from 0 to 4
 - 15 heteroatoms selected from nitrogen, oxygen and sulphur, and
 - bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- 20 ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) R₁₃, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₁₆R₁₇, -OR₁₆, -SO₂R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -X₃(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -X₃(CH₂)_kC(=O)NR₁₆R₁₇, -(CH₂)_kC(=O)NR₁₆R₁₇, -C(=O)O-R₁₉-NR₁₆NR₁₇ and -X₄-R₁₈, in which :
 - 25 - X₃ represents a group selected from oxygen atom, sulphur atom and -NH group,
 - k is an integer from 0 to 3 inclusive,
 - R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

- X_4 represents a group selected from single bond, $-CH_2-$, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
- R_{18} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring, which is optionally substituted by one or more groups, which
5 may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl, and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- R_{19} represents a (C_1-C_6) alkylene group.

The invention also relates to the compounds of general formula (I) in which:

- 10 W is C- R_1 and X is N or C- R_2 in which R_1 and R_2 , identical or different, are selected from hydrogen and methyl,

Y is O,

Z represents an oxygen atom or a $-NH$ group,

n is an integer from 0 to 4 inclusive,

- 15 Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , identical or different, represent a group selected from hydrogen and methyl, and


- when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one double bond,
- and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms,
20 or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_5R_{11}$, $-OR_5$, and $-C(=O)OR_5$, in which R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,

R_3 represents the group of formula:



5

✓ in which p is an integer from 0 to 4 inclusive,

✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen and methyl, and

10

- when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one double bond,
- and/or one of the carbon atoms in the hydrocarbon chain Z_2 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

15

✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

✓ q is an integer from 0 to 7 inclusive,

20

✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_{16}R_{17}$, $-OR_{16}$, $-SO_2R_{16}$, $-(CH_2)_kSO_2NR_{16}R_{17}$, $-X_3(CH_2)_kC(=O)OR_{16}$, $-(CH_2)_kC(=O)OR_{16}$, $-X_3(CH_2)_kC(=O)NR_{16}R_{17}$, $-(CH_2)_kC(=O)NR_{16}R_{17}$, $-C(=O)O-R_{19}-NR_{16}NR_{17}$ and $-X_4-R_{18}$, in which :

- X_3 represents a group selected from oxygen atom, sulphur atom and $-NH$ group,
- k is an integer from 0 to 3 inclusive,

- R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,
- X₄ represents a group selected from single bond, -CH₂-, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
- 5 - R₁₈ represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring, which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxyl, and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- 10 - R₁₉ represents a (C₁-C₆)alkylene group.

The invention also relates to a cyclized quinazoline of general formula (I) in which:

W is C-R₁ and X is N or C-R₂ in which R₁ and R₂, identical or different, are selected from hydrogen and methyl,

Y is O,

- 15 Z represents an oxygen atom or a -NH group,

n is an integer from 0 to 4 inclusive,

Z₁ represents a methylen group, and

- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one double bond,
- 20 ◦ and/or one of the carbon atoms in the hydrocarbon chain Z₁ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,


A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

25

m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₅R₁₁, -OR₅, and -C(=O)OR₅, in which R₅ and R₁₁, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

5 R_3 represents the group of formula:



- ✓ in which p is an integer from 0 to 4 inclusive,
- ✓ Z_2 represents -CR₁₄R₁₅ wherein R₁₄ and R₁₅, independently of each other, represent a group selected from hydrogen and methyl, and when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one double bond,
- 10 ✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,
- 15 ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₁₆R₁₇, -OR₁₆, -SO₂R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -O(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -O(CH₂)_kC(=O)NR₁₆R₁₇, -(CH₂)_kC(=O)NR₁₆R₁₇, and -C(=O)O-R₁₉-NR₁₆NR₁₇ in which :
 - 20 - k is an integer from 0 to 3 inclusive,
 - R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,
 - R₁₉ represents a (C₁-C₆)alkylene group.

The invention also relates to a cyclized quinazoline of general formula (I) wherein n is equal to one.

The invention also relates to a cyclized quinazoline of general formula (I) wherein Z₁ represents a group -CR₉R₁₀ in which R₉ and R₁₀ represent each a hydrogen atom.

- 5 The invention also relates to a cyclized quinazoline of general formula (I) wherein A represents a 5- to 6- membered aromatic monocycle or a 3,4-methylenedioxyphenyl group optionally substituted by one or more groups R₄ as defined in the compound of formula (I).

The invention also relates to a cyclized quinazoline of general formula (I) wherein A represents a phenyl group optionally substituted by one group R₄ as defined in the
10 compound of the formula (I).

The invention also relates to a cyclized quinazoline of general formula (I) wherein A represents a phenyl group, m is equal to one, and R₄ represents a methoxy group or a fluoro group.

The invention also relates to a cyclized quinazoline of general formula (I) wherein A
15 represents a 4-pyridinyl group and m is equal to zero.

The invention also relates to a cyclized quinazoline of general formula (I) wherein Z represents a -NH group and Y represents an oxygen atom, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof.

The invention also relates to a cyclized quinazoline of general formula (I) wherein W
20 represents a -CH group and X represents a nitrogen atom.

The invention also relates to a cyclized quinazoline of general formula (I) wherein R₃ represent a group of formula :



in which p is equal to one, Z₂ represents a methylene group, B represents a phenyl group, q is comprise between 0 to 1 inclusive, R₁₃ represents a group selected from -CN, -(CH₂)_k-C(=O)OR₁₆, -(CH₂)_k-C(=O)NR₁₆R₁₇, and -C(=O)O-R₁₉-NR₁₆NR₁₇ in which k, R₁₆, R₁₇, and R₁₉ are as defined in the compound of formula (I).

5 Among the groups defined above, the following substituents are particularly preferred:

- halogen: F, Cl, Br and I, preferably F, Br and Cl,
- (C₁-C₆)alkyl: linear or branched containing from 1 to 6 and preferably from 1 to 3 carbon atoms,
- 10 - halo(C₁-C₆)alkyl: alkyl substituted with one or more halogen atoms, and preferably trihalogenomethyl,
- (C₁-C₆)alkoxy: linear or branched containing from 1 to 6 and preferably from 1 to 3 carbon atoms,
- (C₂-C₆)alkenyl: containing from 2 to 6 and preferably 2 or 4 carbon atoms, more
- 15 particularly allyl,
- (C₂-C₆)alkynyl: containing from 2 to 6 and preferably 2 or 4 carbon atoms, more particularly propargyl,
- aryl: monocycle or bicycle containing from 5 to 10 and preferably 5 to 6 carbon atoms,
- 20 - heteroaryl: aryl, as defined hereinbefore, in which one to four carbon atoms are replaced by one to four heteroatoms selected from nitrogen, oxygen and sulphur. Examples of such groups containing a heteroatom are, inter alia, furyl, thienyl and pyridyl.
- heterocycle: this term comprises the heteroaryl defined above, the heteroaryl partially hydrogenated and cycloalkyl in which one to four carbon atoms are replaced by
- 25 one to four heteroatoms selected from O, S and N.
- aryl(C₁-C₆)alkyl in which the alkyl contains from 1 to 6 and preferably from 1 to 4 carbon atoms and the aryl contains from 5 to 10 and preferably 5 or 6 carbon atoms,
- cycloalkyl: monocycle or bicycle containing from 3 to 10 and preferably from 3 to 6 carbon atoms,

- cycloalkyl(C₁-C₆)alkyl in which the alkyl contains from 1 to 6 and preferably from 1 to 3 carbon atoms and the cycloalkyl contains from 3 to 10 carbon atoms,
- a multiple bond represent a double bond or a triple bond between two carbon atoms.

5 Among the compounds that are preferred according to the present invention are the following compounds:

- benzyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
 4-pyridylmethyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
N-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-
 10 ylcarboxamide,
N-(4-pyridylmethyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide,
N-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-
 ylcarboxamide,
N-(4-pyridylmethyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide,
 15 *N*-(4-methoxybenzyl)-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-
 carboxamide,
N-[3-(4-pyridylsulphanyl)propyl]-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo-[4,3-*a*]
 quinazoline-7-carboxamide,
N-(3,4-Methylenedioxybenzyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]
 20 quinazol-7-ylcarboxamide
 Methyl 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]
 quinazol-4-ylmethyl} benzoate
 Methyl 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*] quinazol-4-
 ylmethyl} benzoate
 25 Methyl 4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*] quinazol-
 4-ylmethyl} benzoate
 (2-Dimethylamino-ethyl) 4-[7-(4-fluoro-benzylcarbamoyl)-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]
 quinazol-4-ylmethyl] benzoate
 4-(4-Dimethylcarbamoyl-benzyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-
 30 carboxylic acid 4-methoxy-benzylamide

N-(pyridin-4-ylmethyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide

Methyl (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate

5 Methyl (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*] quinazolin-4-ylmethyl}-phenyl)-acetate

Methyl (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate

N-(pyridin-4-ylmethyl) 4-[3-(pyridin-4-yl)-2-propen-1-yl]-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide

4-[2-(4-Chloro-phenoxy)-ethyl]-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxylic acid 4-methoxy-benzylamide

4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

15 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

4-{7-[(4-fluoro)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

(4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid

(4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid, and

25 (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid.

Among the compounds mentioned above, the following compounds are particularly preferred:

benzyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,

30 4-pyridylmethyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,

N-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide,

N-(4-methoxybenzyl)-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxamide,

5 *N*-(3,4-Methylenedioxybenzyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide

Methyl 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate

10 Methyl 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate

4-(4-Dimethylcarbamoyl-benzyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxylic acid 4-methoxy-benzylamide

Methyl (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate

15 Methyl (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate

4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

20 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

4-{7-[(4-fluoro)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid

25 (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid

(4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid, and

30 (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid.

The invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I). A review of the pharmaceutically acceptable salts will be found in J. Pharm. Sci., 1977, vol. 66:1-19. However, the expression "pharmacologically acceptable salts of a compound of formula (I) with a basic function" means the addition salts of the compounds of formula (I) formed from non-toxic mineral or organic acids such as, for example, the salts of hydrobromic acid, hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, acetic acid, succinic acid, tartaric acid, citric acid, maleic acid, hydroxymaleic acid, benzoic acid, fumaric acid, toluenesulphonic acid, isethionic acid and the like. The various quaternary ammonium salts of the compounds of formula (I) are also included in this category of compounds of the invention. In addition, the expression "pharmacologically acceptable salts of a compound of formula (I) with an acid function" means the usual salts of the compounds of formula (I) formed from non-toxic mineral or organic bases such as, for example, the hydroxides of alkali metals and of alkaline-earth metals (sodium, potassium, magnesium and calcium), amines (dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like) or quaternary ammonium hydroxides such as tetramethylammonium hydroxide.

As mentioned above, the compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and particularly inhibitors of the enzyme MMP-13.

In this respect, their use is recommended in the treatment of diseases or complaints involving a therapy by MMP-13 inhibition. By way of example, the use of the compounds of the present invention may be recommended during the treatment of any pathology in which a destruction of the extracellular matrix tissue is involved, and most particularly pathologies such as rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease (COPD), age-related macular degeneration (ARMD) and cancer.

Selectivity of the compounds of formula (I) for the enzyme MMP-13

Most of the matrix metalloprotease inhibitors described in the prior art are non-selective inhibitors, capable of simultaneously inhibiting several matrix metalloproteases. For example, compounds such as CGS-27.023A and AG-3340 (Montana and Baxter

(2000)) simultaneously inhibit MMP-1, MMP-2, MMP-3, MMP-9 and MMP-13, i.e. these compounds of the prior art simultaneously inhibit MMPs of collagenase, gelatinase and stromelysin type.

It has been shown according to the invention that the compounds of general formula (I) constitute selective MMP-13 inhibitors.

The expression "selective inhibitor" of MMP-13 means a compound of formula (I) whose IC₅₀ value for MMP-13 is at least 5 times lower than the IC₅₀ value measured for a matrix metalloprotease other than MMP-13, and preferably at least 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times or 1 000 times lower than the IC₅₀ value measured for a matrix metalloprotease other than MMP-13.

The expression "matrix metalloprotease other than MMP-13" preferably means an MMP selected from from MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14.

In particular, it has been shown according to the invention that the compounds of general formula (I), and more particularly the family of compounds given as examples in the present description, have an IC₅₀ value for the enzyme MMP-13 which is generally 1 000 times less than the value of their IC₅₀ for other matrix metalloproteases, in particular MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14.

The result of this is that the compounds of general formula (I) according to the invention are particularly useful for treating complaints mainly associated with a physiological imbalance between the MMP-13 enzymes and their natural tissue inhibitors.

PHARMACEUTICAL FORMULATION OF THE COMPOUNDS OF THE INVENTION

A subject of the present invention is also a pharmaceutical composition comprising a compound of general formula (I) as defined above and a pharmaceutically acceptable excipient.

The invention also relates to the use of a compound of general formula (I) as defined above for the preparation of a medicinal product intended for treating a disease or complaint involving therapy by inhibition of matrix metalloproteases, and more

particularly a disease or complaint involving therapy by inhibition of type-13 matrix metalloprotease (MMP-13).

An MMP-13-inhibitor compound of general formula (I) according to the invention is particularly useful for treating all pathologies brought about by a degradation of the extracellular matrix tissue, and more particularly for treating rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPDs), age-related macular degeneration (ARMD) and cancer.

In an entirely preferred manner, a compound of general formula (I) as defined according to the invention will be used to treat arthritis, osteoarthritis and rheumatoid arthritis.

The compounds of the invention are administered in the form of compositions that are suitable for the nature and gravity of the complaint to be treated. The daily dosage in man is usually between 2 mg and 1 g of product which may be absorbed in one or more dosage intakes. The compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active principle (compound of formula I) and 40% to 99.5% by weight of pharmaceutically acceptable vehicle.

The compositions of the present invention are thus prepared in forms that are compatible with the desired route of administration. By way of example, the following pharmaceutical forms may be envisaged, although the list given below is not limiting:

1) Forms for oral administration:

Drinkable solutions, suspensions, sachets of powder for drinkable solution, sachets of powder for drinkable suspension, gastro-resistant gel capsules, sustained-release forms, emulsions, HPMR capsules or gel capsules, or lyophilizates to be melted under the tongue.

2) Forms for parenteral administration:

Intravenous route:

Aqueous solutions, water/cosolvent solutions, solutions using one or more solubilizing agents, colloidal suspensions, emulsions, nanoparticulate suspensions which can be used for the injection of sustained-release forms, dispersed forms and liposomes.

Subcutaneous/intramuscular route:

- 5 In addition to the forms which can be used intravenously and which can also be used for the subcutaneous and intramuscular routes, other types of forms such as suspensions, dispersed forms, sustained-release gels and sustained-release implants may also be used.

3) Forms for topical administration:

- 10 Among the most common topical forms that are distinguished are creams, gels (aqueous phases gelled with polymers), patches, which are dressings to be stuck directly onto the skin and which can be used to treat dermatosis without percutaneous penetration of the active substance, sprays, emulsions and solutions.

4) Forms for pulmonary administration

- 15 Forms such as solutions for aerosols, powders for inhalers and other suitable forms are distinguished in this category.

5) Forms for nasal administration:

This especially relates herein to solutions for drops.

6) Forms for rectal administration:

- 20 Suppositories and gels will be selected, inter alia.

It is also possible to envisage using forms allowing the administration of ophthalmic solutions or allowing the vaginal administration of the active principle.

Another important category of pharmaceutical form which may be used in the context of the present invention relates to forms for improving the solubility of the active principle. By way of example, it may be envisaged to use aqueous solutions of cyclodextrin, and more particularly forms comprising hydroxypropyl- β -cyclodextrin. A detailed review of this type of pharmaceutical form is presented in the article published under the reference Journal of Pharmaceutical Sciences, 1142-1169, 85, (11), 1996, and incorporated into the present patent application by reference.


The various pharmaceutical forms recommended above are described in detail in the book "Pharmacie galénique" by A. Lehir (published by Masson, 1992 (6th edition)), which is incorporated into the present patent application by reference.

**PROCESSES FOR SYNTHESIZING INTERMEDIATE COMPOUNDS THAT ARE
USEFUL FOR MANUFACTURING A CYCLIZED QUINAZOLINE OF
FORMULA (I)**

A. First process

This process makes it possible to achieve the synthesis of intermediate compounds that are useful in the manufacture of the compounds of general formula (I) in which W is C-R₁, X is N and R₁, R₃, R₄, Y, Z, Z₁, n, m and A are as defined more generally in the present description.

This process is illustrated in Scheme 1 below:



In Scheme 1 above, T₁ represents an exchangeable group, for example bromine, or a protecting group such as, for example, COOEt, and T₂ represents a group selected from aryl, alkyl and cycloalkyl.


5 In this process, the 2-hydrazino 3,4-dihydroquinazolin-4-one (1a) is coupled, in a first stage, with an alkylcarboxylic, cycloalkylcarboxylic or arylcarboxylic acid chloride (or optionally a phosgene derivative) to give the corresponding hydrazide intermediate, which is cyclized, in a second stage, into a 1-alkyl, cycloalkyl or aryl (or optionally hydroxyl) triazolo[4,3-a]quinazolin-5-one (1b), by heating in a suitable solvent. It is clearly understood that the acid chloride reagent T₂-COCl may be replaced with a reactive
10 derivative of the acid, such as an orthoester.

The process for synthesizing intermediate compounds (1a) is disclosed in the PCT patent application published under No. WO 00/66584.

B. Process 2

15 This process also constitutes a method for synthesizing intermediates that are useful in the manufacture of compounds of formula (I) in which W is C-R₁, X is N and R₁, R₃, R₄, Y, Z, Z₁, n, m and A are as defined more generally in the present description.

This process is illustrated in Scheme 2 below:

Scheme 2

Methyl 4-aminoisophthalate (2a) is treated with benzyl isothiocyanate, in a solvent such as pyridine or acetic acid, to give 3-benzyl-6-(methoxycarbonyl)-2-thioxo-1,2,3,4-tetrahydroquinazolin-4-one (2b). This compound is heated, in a refluxing alcohol, in the presence of hydrazine hydrate to give the corresponding hydrazine which is in turn cyclized by reaction with a carboxylic acid derivative R₁COOH (such as an acid chloride or an orthoester). The 4-benzyl-7-(methoxycarbonyl)-4,5-dihydrotriazolo[4,3-a]quinazolin-5-one (2d) obtained is N4-debenzylated using aluminium chloride in benzene, and the intermediate secondary lactam is then substituted with a halide, in the presence of a base such as cesium carbonate, in a solvent such as dimethylformamide. The N-substituted


analogue obtained (2f) is then hydrolysed, preferably in acidic medium, to give the corresponding acid (2g) which may be subsequently subjected to a coupling reaction of peptide type.

5 The order of the steps in the above process may be modified for the synthesis of certain compounds. For example, when R₃ is para-cyanobenzyl, step 5 will be carried out last since the para-cyanobenzyl group would not withstand the conditions of step 6.

C. Process 3

This process allows the preparation of intermediate compounds that are useful for manufacturing compounds of formula (I) in which W is C-R₁, X is C-R₂ and R₁, R₂, R₃, R₄,
10 Y, Z, Z₁, n, m and A are as defined more generally in the present description.

This preparation process is illustrated in Scheme 3 below:


Scheme 3

3-Benzyl-6-bromo-2-thioxo-1,2,3,4-tetrahydroquinazolin-4-one (3a) is treated, depending on the case, with a 2-amino acetal or a 2-amino ketone, in an alcoholic solvent such as methanol or ethanol, in the presence of a peroxide for initiating the oxidation of the starting thiol and converting it, depending on the circumstance, into a better exchangeable group. The intermediate amino ketone (3d) or amino acetal (3b) obtained is readily cyclized in the presence of acid, in an alcoholic solvent such as isopropanol, into 4-benzyl-6-bromo-4,5-dihydroimidazo[1,2-a]quinazolin-5-one (3c) or (3e) depending on the desired degree of substitution. The bromine atom in position 7 may then be subsequently exchanged with a potential carboxylic function (see, for example, Scheme 5).

D. Process 4

This process allows the synthesis of intermediate compounds that are useful for preparing compounds of formula (I) in which W is N, X is C-R₂ and R₂, R₃, R₄, Y, Z, Z₁, n, m and A are as defined more generally in the present description.

5 This process is illustrated in Scheme 4 below:




10 5-Bromo-2-hydrazinobenzoic acid (4a) is treated with an alkyl N-cyanoimide to give the 4-benzyl-6-bromo-4,5-dihydrotriazolo[2,3-a]quinazolin-5-one (4b) in a single step. This compound is substituted with a halide, in the presence of a base such as cesium carbonate, in a solvent such as dimethylformamide, to give the N4-substituted analogue (4c). The bromine atom in position 7 may then be subsequently exchanged with a potential carboxylic function (see, for example, Scheme 5).

E. Process 5

15 This process illustrates a preferred embodiment of intermediate steps for synthesizing a compound of formula (I) according to the invention, by which the substituent R₃ is introduced into some of the intermediate compounds whose preparation is illustrated by Processes 1 to 4 described above or by Scheme 5 below.

This process for synthesizing intermediate compounds in the manufacture of the compounds of formula (I) according to the invention is illustrated in Scheme 5 below.

Scheme 5



5 In Scheme 5 above, T_3 represents a $(\text{C}_1\text{-C}_6)$ alkyl.

4-Benzyl-7-bromo-4,5-dihydrotriazolo[4,3-a]quinazolin-5-one, triazolo[2,3-a]quinazolin-5-one or imidazo[4,3-a]quinazolin-5-one (5a) is converted into the corresponding 7-cyano derivative (5b) by an exchange reaction with copper cyanide, in a solvent such as N-methylpyrrolidinone. The nitrile function is hydrolysed in acidic medium, for example in the presence of sulphuric acid, and the carboxylic acid (5c) obtained is then esterified to (5d) with an alcohol in acidic medium. This intermediate is

then N4-debenzylated with aluminium chloride, in a solvent such as benzene, and substituted with a halide to give compound (5f), in the presence of a base such as sodium hydride or cesium carbonate, in a solvent such as dimethylformamide or N-methylpyrrolidinone.


The ester (5f) is finally hydrolysed, in acidic medium, to a corresponding carboxylic acid (5g).

The first two steps of Scheme 5 above also apply to the intermediates described above into which R3 has already been introduced.

5 F. Process 6

This process allows the synthesis of intermediate compounds that are useful for manufacturing compounds of formula (I) in which W is N, X is N and R₃, R₄, Y, Z, Z₁, n, m and A are as defined more generally in the present description.

Scheme^o6



10

The process for synthesizing intermediate compounds (6a) is disclosed in the PCT patent application published under WO 00/66584.

The group T₄ represents a protecting group such as CO₂Me or an exchangeable group such as a halogen.

15

The quinazolin-4-one (6a) may be converted into the 4,5-dihydrotriazolo[4,5-a]quinazolin-5-one (6b) by the action of triflic anhydride and sodium azide in a solvent such as acetonitrile.


Instead of the reagents indicated, phosphorus pentachloride and trimethylsilyl azide may also be used to carry out this cyclization.

20


PROCESSES FOR SYNTHESIZING THE COMPOUNDS OF FORMULA (I).**A. PROCESS 1**

5 This process allows the synthesis of compounds of formula (I) in which Y is an oxygen and W, X, R₃, R₄, Z, Z₁, n, m and A are as defined more generally in the present description.

This first process for synthesizing compounds of formula (I) is illustrated in Scheme 7 below:

Scheme 7

In Scheme 7 above, hal represents a halogen, R_8 represents a hydrogen, a (C_1-C_6) alkyl, an aryl (C_1-C_6) alkyl, a cycloalkyl, an aryl or a heteroaryl, R_a represents a hydrogen, a (C_1-C_6) alkyl, an aryl, an aryl (C_1-C_6) alkyl, an aromatic or non-aromatic heterocycle or a cycloalkyl, and R represents the group



in which A, R_4 , Z_1 , m and n are as defined in the compound of general formula (I).


4-Benzyl-7-bromo-4,5-dihydrotriazolo[4,3-a]quinazolin-5-one, triazolo[2,3-a]quinazolin-5-one or imidazo[4,3-a]quinazolin-5-one (5a) bearing an R₃ substitution in position 4 (7a) may be converted into the corresponding ester (7c) or amide (7d) by the direct method A, i.e. coupling with a halide in the presence of a base or activation of the acid function, for example with TOTU, in the presence of DIPEA, followed by displacement of the activated function with an amine; the ester (7c), the amide (7d), the thio acid (7e) or the ketone (7f) may also be obtained by an indirect method B: the acid is converted into the acid chloride (7b) by reaction with thionyl chloride and this compound is then reacted either with an alcohol to give the ester (7c), or with an amine to give the amide (7d), or with a thiol to give the thio ester (7e), or with an organomagnesium reagent to give the ketone (7f).

B. Synthetic process 2

The second preferred process for synthesizing a compound of formula (I) according to the invention allows the manufacture of compounds of formula (I) in which Y is S and W, X, R₃, R₄, Z, Z₁, m, n and A are as defined more generally in the present description.

This process consists essentially in reacting a compound of formula (I) in which Y is O with a suitable reagent, for example Lawesson's reagent.

The said process is illustrated in Scheme 8 below:




4,5-Dihydrotriazolo[4,3-a]quinazolin-5-one, triazolo[2,3-a]quinazolin-5-one or imidazo[4,3-a]quinazolin-5-one bearing an oxygenated function in position 7 (8a; Z = C, O, N) may be converted into the sulphur-containing analogue (8b) by reaction with a reagent such as P₂S₅ or Lawesson's reagent.

C. Synthetic process 3

According to this third process for synthesizing a compound of formula (I), a compound of formula (I) is prepared in which Y is NH, Z is O, N or S and W, X, R₃, R₄, Z₁, m, n and A are as defined more generally in the present description.

- 5 This third process for synthesizing compounds of formula (I) is illustrated in Schemes 9 and 10 below:




- 10 In the above scheme, hal represents a halogen atom and R₈ represents a hydrogen, a (C₁-C₆)alkyl, an aryl(C₁-C₆)alkyl, a cycloalkyl, an aryl or a heteroaryl.

- 15 4,5-Dihydrotriazolo[4,3-a]quinazolin-5-one, triazolo[2,3-a]quinazolin-5-one or imidazo[4,3-a]quinazolin-5-one bearing a nitrile function in position 7 (9a) may be converted into the corresponding imidate (9b) by addition of an alcohol R-OH to the nitrile function, into the corresponding amidine (9c) by addition of an amine R-NH-R₈ to the nitrile function, into the thioimide by addition of a thiol R-SH to the nitrile function, or into the imine by addition of an organomagnesium reagent.

The compounds obtained after the process described in Scheme 9 may be reacted with a group R-X in which R is a (C₁-C₆)alkyl and X is an exchangeable group such as a halogen, in the presence of a base, to give a compound of general formula (I) in which Y is N-R.

5

Scheme 10

In the above scheme, R represents a lower alkyl and Ra represents a hydrogen, a lower alkyl, an aryl, an aralkyl, an aromatic or non-aromatic heterocycle or a cycloalkyl.

10

The present invention is also illustrated, without, however, being limited thereto, by the examples which follow:

EXAMPLES

Example 1:

Benzyl 4-benzyl-5-oxo-4H-[1,2,4]triazolo[4,3-a]quinazolin-7-ylcarboxylate

Intermediate of general formula (5b)

15

1,2,3,4-Tetrahydro-4-benzyl-7-cyano-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one.

20

26.5 g (0.08 mol) of 1,2,3,4-tetrahydro-4-benzyl-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (intermediate of general formula (5a)) and 12.15g (0.14 mol) of copper cyanide are placed in 250 ml of N-methylpyrrolidinone in a reactor fitted with a stirring system and a condenser equipped with a potassium hydroxide guard tube. The mixture obtained is stirred and gradually heated to 220°C and this temperature is then maintained for 3 hours. After partial cooling, the solvent is evaporated off under vacuum; the residue obtained is partitioned between dilute aqueous ammonia and methylene chloride, and the

insoluble material in the two phases is removed by filtration after washing several times with aqueous ammonia and methylene chloride. The organic phase is separated out after settling has taken place, washed with saturated sodium chloride solution, dried over sodium sulphate and then concentrated under vacuum. The residual solid is taken up in 50 ml of ethanol and the insoluble material is spin-filtered and dried under vacuum to give 15.75 g, which is pure by TLC.

The ^1H NMR spectrum is compatible with the expected structure.

Yield = 65%

TLC (CH_2Cl_2 95 / CH_3OH 5): R_f = 0.75

10 Intermediate of general formula (5c)

1,2,3,4-Tetrahydro-4-benzyl-4H-[1,2,4]triazolo[4,3-a]5-oxo-quinazolin-7-ylcarboxylic acid.

A solution of 150 ml of concentrated sulphuric acid in 150 ml of water is prepared, in a round-bottomed flask fitted with a stirrer and a condenser, while cooling externally with an ice bath. 7.0 g (0.023 mol) of 1,2,3,4-tetrahydro-4-benzyl-7-cyano-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (intermediate of general formula (5b)) are added and the mixture is then refluxed with stirring for 2 h 30 min. After cooling, the mixture is filtered and 500 ml of ice-cold water are added to the acidic solution obtained. The precipitate is filtered off, washed several times with water to neutral pH and dried under vacuum to give 5.1 g of solid.

The ^1H NMR spectrum is compatible with the expected structure.

Yield = 69%

The synthesis of Example 1 was carried out according to the 2 methods described in Scheme7:

25 **METHOD A**

0.64 g (0.002 mol) of 1,2,3,4-tetrahydro-4-benzyl-4H-[1,2,4]triazolo[4,3-a]5-oxoquinazolin-7-ylcarboxylic acid are placed in 100 ml of DMF in a reactor equipped with

a condenser and a magnetic stirrer. 0.276 g (0.002 mol) of K_2CO_3 is added and the mixture is stirred at room temperature for 30 minutes.

0.342 g (0.002 mol) of benzyl bromide is then added and the mixture is heated to 100°C and then stirred at this temperature for 15 hours. After evaporating off the solvent under vacuum, the residue is taken up in a mixture of water and ethyl acetate; the insoluble solid in the 2 phases is filtered off, washed with water and an additional small amount of ethyl acetate and then dried under vacuum to give 0.45 g of crude compound (55% of the theoretical amount).

This product is purified by chromatography on a column of silica, eluting with a CH_2Cl_2 99 / CH_3OH 1 mixture: 0.2 g of compound, which is pure by TLC, is obtained.

A recrystallization from acetonitrile gives colourless crystals with a melting point of:

m.p. (Tottoli) = 221°C

TLC(CH_2Cl_2 98 / CH_3OH 2): Rf = 0.4

1H NMR δ (ppm) [DMSO]: 5.4 (s, 2H); 5.45 (s, 2H); 7.3 - 7.55 (m, 10H); 8.35 (d, 1H); 8.5 (d, 1H); 8.75 (s, 1H); 9.6 (s, 1H).

Elemental analysis (%):

Calculated: C70.23; H4.42; N13.65; O11.69

Found: C69.81; H4.32; N13.58; O11.92

METHOD B

0.24 g (0.00075 mol) of 4-benzyl-4H-[1,2,4]triazolo[4,3-a]-5-onequinazol-7-ylcarboxylic acid is placed in suspension in 15 ml of $CHCl_3$ in a reactor fitted with a stirring system, a condenser and a nitrogen inlet, followed by dropwise addition, with stirring at room temperature, of 0.35 ml (0.0045 mol) of thionyl chloride. The mixture is then heated, with stirring, at the reflux temperature of the reagent for 3 hours. After total evaporation of the excess thionyl chloride under vacuum, a solution of 0.116 ml (0.0011 mol) of benzyl alcohol and 0.17 ml (0.0011 mol) of triethylamine in 15 ml of $CHCl_3$ is added and stirring is then continued at room temperature for 1 hour.

The organic phase is washed with water, separated from the aqueous phase by settling and dried over sodium sulphate. After evaporating off the solvent under vacuum, the crude product obtained is purified by chromatography on a column of silica, eluting with a

CH₂Cl₂ (99) / CH₃OH (1) mixture to give 0.1 g of compound, which is pure by TLC (R_f = 0.4; eluent: CH₂Cl₂ 98/ CH₃OH 2).

Yield: 33%

Example 2:

5 **4-Pyridylmethyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate**

The compound of Example 2 is prepared according to the method described in Example 1, using 4-bromomethylpyridine in step A.

Yield = 46%

m.p. (Tottoli) = 232°C

10 ¹H NMR δ (ppm) [DMSO]: 5.4 (s, 2H); 5.5 (s, 2H); 7.25 - 7.4 (m, 3H); 7.45 - 7.55 (m, 4H); 8.4 (d, 1H); 8.55 (d, 1H); 8.65 (d, 2H); 8.8 (s, 1H); 9.65 (s, 1H).

Example 3:

***N*-(3,4-Methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide**

15 0.32 g (0.001 mol) of 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylic acid is dissolved in 15 ml of dry DMF in a reactor protected from moisture, equipped with a stirring system and a thermometer. 0.124 ml (0.001 mol) of 3,4-methylenedioxybenzylamine and 0.328 g (0.001 mol) of TOTU are then added, the mixture is stirred, the solution obtained is cooled to 0-5°C and 0.258 mg (0.002 mol) of DIPEA is then added. The solution is stirred under cold conditions for a few minutes and
20 then at room temperature for 15 hours.

After evaporating off the solvent under vacuum, the residue is taken up in methylene chloride and the insoluble material is separated out by filtration, washed with a small additional amount of CH₂Cl₂ and then dried under vacuum to give 0.35 g of crude compound (77% of theoretical amount).

25 0.3 g of this product is recrystallized from dioxane to give 0.15 g of product which is pure by TLC.(R_f = 0,35; eluent: CH₂Cl₂ (80) / CH₃OH (20)).

m.p. (Tottoli) = 273°C (dec)

¹H NMR δ (ppm) [DMSO]: 4.45 (d, 2H); 5.45 (s, 2H); 6.0 (s, 2H); 6.8 - 7.0 (m, 3H); 7.25 - 7.4 (m, 3H); 7.5 (m, 2H); 8.3 (d, 1H); 8.4 (d, 1H); 8.8 (s, 1H); 9.35 (t, 1H); 9.6 (s, 1H).

Example 4:

N-(4-Pyridylmethyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide

The compound of Example 4 is prepared in the same way as in Example 3, but using 4-pyridylmethylamine.

Yield = 50%

m.p. (Tottoli) = 273°C

¹H NMR δ (ppm) [DMSO]: 4.5 (d, 2H); 5.4 (d, 2H); 7.3 - 7.4 (m, 5H); 7.5 (m, 2H); 8.35 (d, 1H); 8.45 (d, 1H); 8.5 (d, 2H); 8.8 (s, 1H); 9.5 (t, 1H); 9.6 (s, 1H).

Example 5:

N-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide

Intermediate of general formula (3d)

*1,2,3,4-Tetrahydro-3-benzyl-6-bromo-2-[N-(2,2-dimethoxyethyl)imino]-4*H*-quinazolin-4-one.*

6.4 g (0.0184 mol) of 1,2,3,4-tetrahydro-3-benzyl-6-bromo-2-thioxo-4*H*-quinazolin-4-one, 10.1 ml (0.092 mol) of 2-aminoacetaldehyde dimethyl acetal and 8.3 ml (0.0645 mol) of aqueous 70% t-butyl hydroperoxide are placed in 575 ml of dry methanol in a round-bottomed flask equipped with a stirrer and a condenser fitted with a potassium hydroxide guard tube. The suspension is stirred at room temperature for 24 h. Aqueous potassium metabisulphite solution is added to neutralize any residual excess of peroxides, and the mixture is then concentrated to a small volume. The precipitate is filtered off, washed with water and then with methanol, and dried under vacuum.

2.53 g of a crude solid are obtained, which product is used in its current form for the next step. The ¹H NMR spectrum is compatible with the expected structure.

Yield = 33%

Intermediate of general formula (3e)

1,2,3,4-Tetrahydro-4-benzyl-7-bromo-4H-imidazo[1,2-a]quinazolin-5-one.

5 2.87 g (0.0067 mol) of 1,2,3,4-tetrahydro-3-benzyl-6-bromo-2-[N-(2,2-dimethoxyethyl)imino]-4H-quinazolin-4-one (intermediate of general formula (3d)) are dissolved in a mixture of 20 ml of 3N hydrochloric acid solution and 70 ml of isopropanol in a round-bottomed flask equipped with a stirrer and a condenser. The solution is refluxed for 4 h with stirring. The isopropanol is evaporated off under vacuum and the residue is
10 partitioned between sodium bicarbonate solution and methylene chloride. The organic phase is separated out after settling has taken place, washed with saturated sodium chloride solution, dried over sodium sulphate and then concentrated to dryness to give 2.1 g of crude compound.

The ¹H NMR spectrum is compatible with the expected structure.

15 Yield = 88%

Intermediate of general formula (5b)

1,2,3,4-Tetrahydro-4-benzyl-7-cyano-4H-imidazo[1,2-a]quinazolin-5-one.

2.4 g (0.0068 mol) of 1,2,3,4-tetrahydro-4-benzyl-7-bromo-4H-imidazo[1,2-a]quinazolin-5-one are treated with 1.1 g (0.0123 mol) of copper cyanide in 25 ml of N-methylpyrrolidinone, according to the process for synthesizing the intermediate of general
20 formula (5b). The crude residue obtained is purified by chromatography on silica, eluting with a CH₂Cl₂ 98.5 / CH₃OH 1.5 mixture. 1.15 g of a coloured solid are obtained.

The ¹H NMR spectrum is compatible with the expected structure.

Yield = 56.5%

25 TLC (CH₂Cl₂ 98 / CH₃OH 2): R_f = 0.55

Intermediate of general formula (5c)

1,2,3,4-Tetrahydro-4-benzyl-5-oxoimidazo[1,2-a]quinazolin-7-ylcarboxylic acid.

0.63 g (0.0021 mol) of 1,2,3,4-tetrahydro-4-benzyl-7-cyano-4*H*-imidazo[1,2-*a*]quinazolin-5-one is treated with 30 ml of a 50/50 mixture of concentrated sulphuric acid and water according to the method for synthesizing the intermediate of general formula (5c). After filtering off the precipitate obtained by dilution, washing and drying, 0.6 g of the expected compound, which is pure by TLC, is obtained.

The ¹H NMR spectrum is compatible with the expected structure.

Yield = 89.5%

TLC (CH₂Cl₂ 90 / CH₃OH 10): R_f = 0.20

Synthesis of Example 5: *N*-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide

0.3 g (0.00094 mol) of 4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxylic acid is dissolved in 15 ml of dry dimethylformamide in a reactor equipped with a condenser and a magnetic stirrer. 0.117 ml (0.00094 mol) of 3,4-methylenedioxybenzylamine and 0.308 g (0.00094 mol) of TOTU are then added, the mixture is stirred, the solution obtained is cooled to 0-5°C and 0.327 ml (0.0019 mol) of DIPEA is then added.

A work-up identical to that of Example 3, followed by chromatography of the crude product on a column of silica, eluting with a CH₂Cl₂ 98 / CH₃OH 9 mixture gives 0.32 g of compound, which is pure by TLC (75% of the theoretical amount).

Recrystallization from ethanol gives colourless crystals with a melting point of:

m.p. (Tottoli) = 189°C

TLC (CH₂Cl₂ 98 / CH₃OH 2): R_f = 0.5

¹H NMR δ (ppm) [DMSO]: 4.45 (d, 2H); 5.45 (s, 2H); 6.0 (s, 2H); 6.8 – 6.9 (m, 2H); 6.95 (s, 1H); 7.2 (s, 1H); 7.25 – 7.35 (m, 3H); 7.4 (m, 2H); 8.15 (m, 2H); 8.35 (d, 1H); 8.8 (s, 1H); 9.3 (t, 1H).

Example 6:

***N*-(4-Pyridylmethyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide**

The compound of Example 6 is prepared in the same way as that of Example 5, but using 4-pyridylmethylamine in the final step.

Yield = 86%

m.p. (Tottoli) = 251°C

TLC (CH₂Cl₂ 95 / CH₃OH 5): R_f = 0.4

5 **¹H NMR δ (ppm) [DMSO]: 4.55 (d, 2H); 5.45 (s, 2H); 7.2 (s, 1H); 7.25 – 7.4 (m, 5H); 7.5 (m, 2H); 8.2 (m, 2H); 8.4 (d, 1H); 8.55 (d, 2H); 8.85 (s, 1H); 9.5 (t, 1H).**

Example 7:

***N*-(4-Methoxybenzyl)-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxamide**

10 The compound of Example 7 is prepared in the same way as in Example 3, but using 4-methoxybenzylamine.

m.p. (Tottoli) = 255°C

¹H NMR δ (ppm) [DMSO]: 3.75 (s, 3H); 4.45 (d, 2H); 5.4 (s, 2H); 6.9 (d, 2H); 7.2 – 7.35 (m, 5H); 7.45 (m, 2H); 8.3 (d, 1H); 8.4 (d, 1H); 8.8 (s, 1H); 9.35 (t, 1H); 9.55 (s, 1H).

Example 8:

15 ***N*-[3-(4-Pyridylsulphanyl)propyl]-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxamide**

The compound of Example 8 is prepared in the same way as in Example 3, but using 3-(4-pyridylsulphanyl)propylamine.

m.p. (Tottoli) = 130°C

20 **¹H NMR δ (ppm) [DMSO]: 1.9 – 2.0 (m, 2H); 3.1 – 3.2 (m, 2H); 3.4 – 3.5 (m, 2H); 5.4 (s, 2H); 7.2 – 7.35 (m, 5H); 7.45 (d, 2H); 8.3 (d, 1H); 8.35 – 8.4 (m, 3H); 8.75 (d, 1H); 8.9 – 9.0 (t, 1H); 9.55 (s, 1H).**

Exemple 9 :

25 ***N*-(3,4-Methylenedioxybenzyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide**

0.7 g (1.9 mmol) of *N*-(3,4-methylenedioxybenzyl)-4*H*-[1,2,4]triazolo[4,3-*a*]-5-oxo-quinazol-7-yl carboxamide in suspension in 20 ml of dimethylformamide and 0.62 g (1.9

mmol) of cesium carbonate are placed in a reactor fitted with a stirring system. The mixture is stirred 15 minutes at room temperature and 0.372 g (1.9 mmol) of 4-cyanobenzyl bromide is added. The reaction mixture is stirred at 90°C for 12 hours and concentrated under vacuum. The residu obtained is taken up in a mixture of water and dichloromethane. The organic phase is separated, washed with brine and evaporated under vacuum. A chromatography of the residu over silica gel (dichloromethane/methanol : 95/5) yield 0.55 g (60%) of the desired compound pure on TLC. A recrystallisation from acetonitrile give 0.32 of uncolourless crystals.

m.p. (Tottoli) = 215°C

¹H NMR δ (ppm) [DMSO] : 4.4 (d, 2H) ; 5.45 (s, 2H) ; 6.0 (s, 2H) ; 6.8-6.9 (m, 2H) ; 6.95 (s, 1H) ; 7.6 (m, 2H) ; 7.8 (m, 2H) ; 8.3 (m, 2H) ; 8.4 (m, 1H) ; 8.8 (s, 1H) ; 9.3 (t, 1H) ; 9.6 (s, 1H).

The following compounds are obtained using a similar process described for the compound of Example 9:

Example 10 :

Methyl 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate




m.p. (Tottoli) = 248°C

¹H NMR δ (ppm) [DMSO] : 3.8 (s, 3H) ; 4.4 (d, 2H) ; 5.5 (s, 2H) ; 6.0 (s, 2H) ; 6.8 – 6.95 (m, 3H) ; 7.55 (d, 2H) ; 7.95 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.8 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

Example 11:

Methyl 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate

56




m.p. (Tottoli) = 210°C

¹H NMR δ (ppm) [DMSO] : 3.7 (s, 3H) ; 3.8 (s, 3H) ; 4.4 (d, 2H) ; 5.4 (s, 2H) ; 6.9 (d, 2H) ; 7.3 (d, 2H) ; 7.6 (d, 2H) ; 7.9 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.75 (s, 1H) ; 9.35 (t, 1H) ; 9.55 (s, 1H).

Example 12 :

Methyl 4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl} benzoate




m.p. (Tottoli) = 235°C

¹H NMR δ (ppm) [DMSO] : 3.8 (s, 3H) ; 4.5 (d, 2H) ; 5.4 (s, 2H) ; 7.3 (d, 2H) ; 7.6 (d, 2H) ; 7.9 (d, 2H) ; 8.3 (d, 1H) ; 8.45 (d, 1H) ; 8.5 (d, 2H) ; 8.8 (s, 1H) ; 9.5 (t, 1H) ; 9.6 (s, 1H).

Example 13 :

(2-Dimethylamino-ethyl) 4-[7-(4-fluoro-benzylcarbamoyl)-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl] benzoate




m.p. (Tottoli) = 175°C

¹H NMR δ (ppm) [DMSO] : 2.2 (s, 2H) ; 2.6 (t, 2H) ; 4.3 (t, 2H) ; 4.5 (d, 2H) ; 5.4 (s, 2H) ; 7.2 (t, 2H) ; 7.4 (m, 2H) ; 7.6 (d, 2H) ; 7.9 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.7 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

Exemple 14:


4-(4-Dimethylcarbamoyl-benzyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxylic acid 4-methoxy-benzylamide



- 5 ^1H NMR δ (ppm) [DMSO] : 2.9 (s, 3H) ; 2.95 (s, 3H) ; 3.7 (s, 3H) ; 4.4 (d, 2H) ; 5.4 (s, 2H) ; 6.8 (d, 2H) ; 7.25 (d, 2H) ; 7.35 (d, 2H) ; 7.5 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.8 (s, 1H) ; 9.3 (t, 1H) ; 9.55 (s, 1H).

Exemple 15 :

- 10 ***N*-(pyridin-4ylmethyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide**




m.p. (Tottoli) = 300°C

^1H NMR δ (ppm) [DMSO] : 4.5 (d, 2H) ; 5.5 (s, 2H) ; 7.35 (m, 2H) ; 7.8 (m, 2H) ; 8.35 (m, 1H) ; 8.45 (m, 1H) ; 8.5 (m, 2H) ; 8.8 (s, 1H) ; 9.5 (t, 1H) ; 9.6 (s, 1H).

- 15 **Exemple 16 :**

Methyl (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate




m.p. (Tottoli) = 231°C

- 20 ^1H NMR δ (ppm) [DMSO] : 3.6 (s, 3H) ; 3.65 (s, 2H) ; 4.2 (d, 2H) ; 5.4 (s, 2H) ; 6.0 (s, 2H) ; 6.8-6.9 (m, 3H) ; 7.2 (d, 2H) ; 7.4 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.75 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

Exemple 17 :

Methyl (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl}-phenyl)-acetate




5 **m.p. (Tottoli) = 204°C**

¹H NMR δ (ppm) [DMSO] : 3.6 (s, 3H) ; 3.65 (s, 2H) ; 3.7 (s, 3H) ; 4.45 (d, 2H) ; 5.4 (s, 2H) ; 6.9 (d, 2H) ; 7.2 (d, 2H) ; 7.3 (d, 2H) ; 7.4 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.75 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

Exemple 18:

10 **Methyl (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl}-phenyl)-acetate**




m.p. (Tottoli) = 192°C

15 **¹H NMR δ (ppm) [DMSO] :** 3.3 (s, 3H) ; 3.6 (s, 2H) ; 4.55 (d, 2H) ; 5.35 (s, 2H) ; 7.2 (m, 2H) ; 7.3-7.4 (m, 4H) ; 8.3 (m, 1H) ; 8.4 (m, 1H) ; 8.5 (s, 1H) ; 9.5 (t, 1H) ; 9.6 (s, 1H).

Exemple 19 :

N-(pyridin-4-ylmethyl) 4-[3-(pyridin-4-yl)-2-propen-1-yl]-5-oxo-4H-[1,2,4]triazolo[4,3-a]quinazol-7-ylcarboxamide




20 **m.p. (Tottoli) = 250°C**

¹H NMR δ (ppm) [DMSO] : 4.5 (d, 2H) ; 5 (d, 2H) ; 6.6-6.8 (m, 2H) ; 7.3 (m, 2H) ; 8.3 (m, 1H) ; 8.4-8.6 (m, 3H) ; 8.8 (s, 1H) ; 9.5-9.6 (m, 2H).

Exemple 20 :

4-[2-(4-Chloro-phenoxy)-ethyl]-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazoline-7-carboxylic acid 4-methoxy-benzylamide




m.p. (Tottoli) = 186°C

¹H NMR δ (ppm) [DMSO] : 3.7 (s, 3H) ; 4.4 (t, 2H) ; 4.45 (d, 2H) ; 4.6 (t, 2H) ; 6.9 (m, 4H) ; 7.3 (m, 4H) ; 8.2 (d, 1H) ; 8.4 (dd, 1H) ; 8.7 (d, 1H) ; 9.4 (t, 1H) ; 9.5 (s, 1H).

10

Exemple 21:

4-{7-[(4-Methoxybenzyl)-carbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl} benzoic acid



15

8.8 g (17.7 mmol) of compound obtained in the Example 11 in suspension in 900 ml of a mixture (water/methanol : 50/50) and 2.45 g (17.7 mmol) of potassium carbonate are placed in a reactor fitted with a stirring system. The mixture is heated under reflux for 45 minutes and 2.45 g (17.7 mmol) of potassium carbonate are added. After 30 minutes of stirring under reflux, the reaction mixture is partially concentrated under vacuum and a mixture of ice acetic acid and ice is added to provide a precipitate which is filtered, washed with water until neutral pH, and then with methanol. After dried under vacuum, 6.1 g (yield = 61%) of the uncolourless desired product are obtained.


20

¹H NMR δ (ppm) [DMSO] : 3.8 (s, 3H) ; 4.45 (d, 2H) ; 5.45 (s, 2H) ; 6.9 (d, 2H) ; 7.3 (d, 2H) ; 7.55 (d, 2H) ; 8.3 (d, 2H) ; 8.4 (d, 1H) ; 8.75 (s, 1H) ; 9.4 (t, 1H) ; 9.55 (s, 1H) ; 12.9 (s, 1H).

The following compounds are obtained using a similar process described for the compound of Example 21:

Exemple 22 :

- 5 4-{7-[(1,3-Benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl} benzoic acid




m.p. (Tottoli) = 235°C

- 10 ¹H NMR δ (ppm) [DMSO] : 4.4 (d, 2H) ; 5.4 (s, 2H) ; 6.0 (s, 2H) ; 6.8 (m, 2H) ; 6.9 (d, 2H) ; 7.5 (d, 2H) ; 7.9 (d, 2H) ; 8.3 (d, 2H) ; 8.4 (d, 2H) ; 8.75 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

Exemple 23 :

- 4-{7-[(Pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl} benzoic acid



15

m.p. (Tottoli) = 255°C


¹H NMR δ (ppm) [DMSO] : 4.55 (d, 2H) ; 5.5 (s, 2H) ; 7.3 (d, 2H) ; 7.55 (d, 2H) ; 7.9 (d, 1H) ; 8.3 (d, 1H) ; 8.4 (d, 2H) ; 8.5 (d, 2H) ; 8.8 (s, 1H) ; 9.5 (t, 1H) ; 9.6 (s, 1H) ; 13.0 (m, 1H).

20

Exemple 24 :

- 4-{7-[(4-Fluoro)-benzylcarbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazol-4-ylmethyl} benzoic acid

61




m.p. (Tottoli) = 303°C

¹H NMR δ (ppm) [DMSO] : 4.5 (d, 2H) ; 5.6 (s, 2H) ; 7.2 (m, 2H) ; 7.4 (m, 2H) ; 7.6 (d, 2H) ; 7.9 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 2H) ; 8.8 (s, 1H) ; 9.4 (t, 1H) ; 9.6 (s, 1H).

5 **Exemple 25 :**

(4-{7-[(4-Methoxy)-benzylcarbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a] quinazolin-4-ylmethyl}-phenyl)-acetic acid




m.p. (Tottoli) = 268°C

10 ¹H NMR δ (ppm) [DMSO] : 3.5 (s, 2H) ; 3.7 (s, 3H) ; 4.45 (d, 2H) ; 5.4 (s, 2H) ; 6.9 (d, 2H) ; 7.2 (d, 2H) ; 7.3 (d, 2H) ; 7.4 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.8 (s, 1H) ; 9.4 (t, 1H) ; 9.5 (t, 1H) ; 12.2 (m, 1H).

Exemple 26 :

15 (4-{7-[(1,3-Benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5H-[1,2,4]triazolo [4,3-a]quinazolin-4-ylmethyl}-phenyl)-acetic acid




m.p. (Tottoli) = 232°C

20 ¹H NMR δ (ppm) [DMSO] : 3.4 (s, 2H) ; 4.4 (d, 2H) ; 5.3 (s, 2H) ; 6.0 (s, 2H) ; 6.8-6.9 (m, 3H) ; 7.2 (d, 2H) ; 7.3 (d, 2H) ; 8.3 (d, 1H) ; 8.4 (d, 1H) ; 8.7 (s, 1H) ; 9.3 (t, 1H) ; 9.5 (s, 1H).

Exemple 27:

(4-{7-[(Pyridin-4-yl)-methylcarbamoyl]-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl}-phenyl)-acetic acid



¹H NMR δ (ppm) [DMSO]: 3.5 (s, 3H); 4.5 (d, 2H); 5.4 (s, 2H); 7.2 (d, 2H); 7.3 (d, 2H); 7.4 (d, 2H); 8.3 (d, 1H); 8.4 (d, 1H); 8.5 (d, 2H); 8.8 (s, 1H); 9.5 (t, 1H); 9.6 (s, 1H).

Example 28: Evaluation of the in vitro activity of the MMP-13-inhibitor compounds according to the invention.

The inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 was evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP-13.

The peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester-Leu-Leu-Gly-OEt.

The inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC₅₀ value, which is the concentration of inhibitor for which an inhibition of 50% of the activity of the matrix metalloprotease under consideration is observed.

To carry out this test, a reaction medium of 100 μl volume is prepared, containing: 50 mM of HEPES buffer, 10 mM of CaCl₂ and 1 mM of 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), and 100 μM of substrate, the pH being adjusted to 7.0.

Increasing concentrations of the inhibitory compound present in a 2.0% DMSO solution and 2.5 nM of the catalytic domain of human MMP-13 are added to the test samples.

The concentrations of inhibitors present in the test samples range from 100 μM to 0.5 nM.

The measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbance at 405 nm using a spectrophotometric machine for reading

microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes.

The IC₅₀ values are calculated from the curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.

The IC₅₀ values on MMP-13 of the compounds of Examples 1 to 6 are given in Table 1 below.

Table 1

Example	IC ₅₀ (μM)
1	0.0034
2	0.0023
3	0.0040
4	0.040
5	0.165

The test described above for the inhibition of MMP-13 was also adapted and used to determine the ability of the compounds of formula (I) to inhibit the matrix metalloproteases MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14.

The results obtained show that the cyclized quinazoline compounds according to the invention generally have IC₅₀ values for MMP-13 which are about 100 times lower than the IC₅₀ values for the same compounds with respect to the other matrix metalloproteases tested.

Bibliographic references


MONTANA J. and BAXTER A., Current opinion in drug discovery and development, 3 (4), 353-361, (2000).

CLARK IM et al., Current opinion in anti-inflammatory and immunomodulatory investigational drugs, 2 (1), 16-25, (2000).

Claims

1 – A compound selected from those of formula (I):

The invention relates to cyclized quinazolines of formula (I)



5 in which:

W represents N or C-R₁; in which R₁ is selected from:

- hydrogen atom,
 - OR₅, SR₅ in which R₅ is selected from hydrogen, (C₁-C₆)alkyl and aryl(C₁-C₆)alkyl,
 - (C₁-C₆)alkyl, cycloalkyl of 3 to 8 carbon atoms optionally interrupted with one hetero
- 10 atom selected from oxygen, sulfur and nitrogen, aryl, heteroaryl and aryl(C₁-C₆)alkyl, these groups being optionally substituted by (CH₂)_p-OH or (CH₂)_p-NH₂, in which p is an integer from 0 to 4 inclusive,

X represents N or C-R₂ in which R₂ is selected from:

- hydrogen atom,
 - 15 • NR₆R₇, OR₆, SR₆ in which R₆ and R₇, identical or different, are selected from hydrogen, (C₁-C₆)alkyl and aryl(C₁-C₆)alkyl,
 - (C₁-C₆)alkyl, cycloalkyl of 3 to 8 carbon atoms optionally interrupted with one hetero
- atom selected from oxygen, sulfur and nitrogen, aryl, heteroaryl and aryl(C₁-C₆)alkyl, these groups being optionally substituted by (CH₂)_p-OH or (CH₂)_p-NH₂, in which p is an
- 20 integer from 0 to 4 inclusive,

Y represents a group selected from oxygen, sulfur, -NH, and -N(C₁-C₆)alkyl,

Z represents a group selected from:

- oxygen, sulphur,
 - and $-NR_8$ in which R_8 represents a group selected from hydrogen, (C_1-C_6) alkyl, aryl (C_1-C_6) alkyl, cycloalkyl, aryl, and heteroaryl, and
 - when Y is oxygen, sulphur, or $-N(C_1-C_6)$ alkyl, Z optionally represents a carbon atom
- 5 which is optionally substituted by a group selected from (C_1-C_6) alkyl, aryl, aryl (C_1-C_6) alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl,

n is an integer from 0 to 8 inclusive,

Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , identical or different, represent a group selected from hydrogen, (C_1-C_6) alkyl, halo (C_1-C_6) alkyl, halogen, NR_5R_{11} , OR_5 , SR_5 and

10 $C(=O)OR_5$ in which R_5 and R_{11} , identical or different, represents hydrogen atom or (C_1-C_6) alkyl, and

- when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one or more multiple bonds,
 - and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an
- 15 oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

A represents a group selected from :


- aromatic or non-aromatic, 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, and
 - bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which
- 20 may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-NO_2$, $-SCF_3$, $-CF_3$, $-OCF_3$, $-NR_5R_{11}$, $-OR_5$, $-SR_5$, $-SOR_5$, $-SO_2R_5$,

25 $-(CH_2)_kSO_2NR_5R_{11}$, $-X_1(CH_2)_kC(=O)OR_5$, $-(CH_2)_kC(=O)OR_5$, $-X_1(CH_2)_kC(=O)NR_5R_{11}$, $-(CH_2)_kC(=O)NR_5R_{11}$, and $-X_2-R_{12}$ in which:

- X_1 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by hydrogen or (C_1-C_6) alkyl,
- k is an integer from 0 to 3 inclusive,
- R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
- X_2 represents a group selected from single bond, $-CH_2-$, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C_1-C_6) alkyl group,
- R_{12} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- R_3 represents a group selected from:
 - hydrogen,
 - (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, these groups being optionally substituted by one or more groups, which may be identical or different, selected from amino, cyano, halo (C_1-C_6) alkyl, cycloalkyl, $-C(=O)NR_5R_{11}$, $-C(=O)OR_5$, $-OR_5$, and $-SR_5$, in which R_5 and R_{11} , which may be identical or different, are as defined hereinbefore,
 - and the group of formula :



✓ in which p is an integer from 0 to 8 inclusive,

✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen, (C_1-C_6) alkyl, phenyl, halo (C_1-C_6) alkyl, halogen, amino, $-OR_5$,

-NR₅R₁₁, -SR₅ and -C(=O)OR₅ in which R₅ and R₁₁, identical or different, are as defined hereinbefore, and

- when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one or more multiple bonds,
- 5 - and/or one of the carbon atoms in the hydrocarbon chain Z₂ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,
- ✓ B represents a group selected from:
 - aromatic or non-aromatic 5- or 6-membered monocycle comprising from 0 to 4
 - 10 heteroatoms selected from nitrogen, oxygen and sulphur, and
 - bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- ✓ q is an integer from 0 to 7 inclusive,
- 15 ✓ the group(s) R₁₃, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -NO₂, -CF₃, -OCF₃, (C₁-C₆)acyl, -(CH₂)_kNR₁₆R₁₇, -X₃-(CH₂)_kNR₁₆R₁₇, -N(R₁₆)C(=O)R₁₇, -N(R₁₆)C(=O)OR₁₇, -N(R₁₆)SO₂R₁₇, -N(SO₂R₁₆)₂, -OR₁₆, -S(O)_{k1}R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -X₃(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -X₃(CH₂)_kC(=O)NR₁₆R₁₇, -(CH₂)_kC(=O)NR₁₆R₁₇,
 - 20 -C(=O)O-R₁₉-NR₁₆NR₁₇ and -X₄-R₁₈, in which :
 - X₃ represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by a hydrogen atom or a (C₁-C₆)alkyl group,
 - k is an integer from 0 to 3 inclusive,
 - 25 - k₁ is an integer from 0 to 2 inclusive,
 - R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

- X_4 represents a group selected from single bond, $-CH_2-$, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C_1-C_6) alkyl group,
- R_{18} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or
5 6-membered ring, which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl, (C_1-C_6) alkoxy, oxo, cyano, tetrazole, $-NR_5R_{11}$, and $-C(=O)OR_5$ wherein R_5 and R_{11} are as defined hereinbefore, and, when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
- R_{19} represents a (C_1-C_6) alkylene group,
10 optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof,

it being understood that:

- aryl represents a monocycle or bicycle containing from 5 to 10 and preferably 5 to 6 carbon atoms,
- heteroaryl represents aryl, as defined hereinbefore, in which one to four carbon atoms are replaced by one to four heteroatoms selected from nitrogen, oxygen and sulphur,
- cycloalkyl represents monocycle or bicycle containing from 3 to 10 and preferably from 3
20 to 6 carbon atoms,
- heterocycle represents heteroaryl as defined above, heteroaryl partially hydrogenated and cycloalkyl as defined above in which one to four carbon atoms are replaced by one to four heteroatoms selected from oxygen, sulphur and nitrogen,
- aryl (C_1-C_6) alkyl represents a group in which alkyl contains from 1 to 6 and preferably
25 from 1 to 4 carbon atoms and aryl contains from 5 to 10 and preferably 5 or 6 carbon atoms,
- cycloalkyl (C_1-C_6) alkyl represents a group in which alkyl contains from 1 to 6 and preferably from 1 to 3 carbon atoms and cycloalkyl contains from 3 to 10 carbon atoms.

2- A compound according to claim 1 characterized in that:

- 30 W is $C-R_1$ and X is N or $C-R_2$ in which R_1 and R_2 , identical or different, are selected from hydrogen and methyl,

Y is O,

Z represents an oxygen atom or -NH group,

n is an integer from 0 to 4 inclusive,

5 Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , identical or different, represent a group selected from hydrogen, (C_1-C_6) alkyl, halo (C_1-C_6) alkyl, halogen, $-NR_5R_{11}$, $-OR_5$, $-SR_5$ and $-C(=O)OR_5$ in which R_5 and R_{11} , identical or different, represent hydrogen atom or (C_1-C_6) alkyl, and

- when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one double bonds,
- 10 • and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

15 R_3 , R_4 and A are as defined in the compound of formula (I), optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

3- A compound according to claim 1 characterized in that:

R_3 represents the group of formula :



✓ in which p is an integer from 0 to 4 inclusive,

20 ✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen and methyl, and when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one double bond,

✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

✓ q is an integer from 0 to 7 inclusive,

5 ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, -CN, -CF₃, -NR₁₆R₁₇, -OR₁₆, -SO₂R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -O(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -O(CH₂)_kC(=O)NR₁₆R₁₇, -C(=O)O-R₁₉-NR₁₆NR₁₇ and -(CH₂)_kC(=O)NR₁₆R₁₇, in which k is an integer from 0 to 3 inclusive, R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen
10 and (C_1-C_6) alkyl, and R₁₉ represents a (C_1-C_6) alkylene group,

W, X, Y, Z, Z₁, n, m, A and R₄ are as defined in the compound of formula (I), optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

4- A compound according to claim 1 characterized in that:

n is an integer from 0 to 4 inclusive,

15

Z₁ represents a group -CR₉R₁₀ wherein R₉ and R₁₀ represent each hydrogen atom, and

- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one double bond,
- and/or one of the carbon atoms in the hydrocarbon chain Z₁ may be replaced with an
20 oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

25 m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_5R_{11}$, $-OR_5$, and $-C(=O)OR_5$ in which R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,

- W, X, Y, Z and R_3 are as defined in the compound of formula (I),
5 optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

5- A compound according to claim 1 characterized in that:

W is $C-R_1$ and X is N or $C-R_2$ in which R_1 and R_2 , identical or different, are selected from hydrogen and methyl,

- 10 Y is O,

Z represents an oxygen atom or $-NH$ group,

n is an integer from 0 to 4 inclusive,

Z_1 represents a group $-CR_9R_{10}$ wherein R_9 and R_{10} , identical or different, represent a group selected from hydrogen and methyl, and

- 15 • when n is greater than or equal to 2, the hydrocarbon chain Z_1 optionally contains one or more multiple bonds,
• and/or one of the carbon atoms in the hydrocarbon chain Z_1 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,

- 20 A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

m is an integer from 0 to 7 inclusive,

the group(s) R_4 , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, $-CN$, $-CF_3$, $-NR_5R_{11}$, $-OR_5$, $-SO_2R_5$, $-(CH_2)_kSO_2NR_5R_{11}$, $-X_1(CH_2)_kC(=O)OR_5$, $-(CH_2)_kC(=O)OR_5$, $-X_1(CH_2)_kC(=O)NR_5R_{11}$, $-(CH_2)_kC(=O)NR_5R_{11}$, and $-X_2-R_{12}$ in which:

- ✓ X_1 represents a group selected from oxygen, sulphur and $-NH$,
- 5 ✓ k is an integer from 0 to 3 inclusive,
- ✓ R_5 and R_{11} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
- ✓ X_2 represents a group selected from single bond, $-CH_2-$, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
- 10 ✓ R_{12} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from
- 15 nitrogen, oxygen and sulphur;

R_3 represents the group of formula:



- ✓ in which p is an integer from 0 to 6 inclusive,
- 20 ✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen, (C_1-C_6) alkyl, phenyl, halo (C_1-C_6) alkyl, halogen, amino, OR_5 , SR_5 and $-C(=O)OR_5$ in which R_5 is as defined in the compound of formula (I), and
 - when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one or more multiple bonds,

- and/or one of the carbon atoms in the hydrocarbon chain Z_2 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,
 - ✓ B represents a group selected from:
 - 5 • aromatic or non-aromatic 5- or 6-membered monocycle comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, and
 - bicycle, composed of two aromatic or non-aromatic, 5- or 6-membered rings, which may be identical or different, comprising from 0 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
 - 10 ✓ q is an integer from 0 to 7 inclusive,
 - ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, -CN, $-CF_3$, $-NR_{16}R_{17}$, $-OR_{16}$, $-SO_2R_{16}$, $-(CH_2)_kSO_2NR_{16}R_{17}$, $-X_3(CH_2)_kC(=O)OR_{16}$, $-(CH_2)_kC(=O)OR_{16}$, $-X_3(CH_2)_kC(=O)NR_{16}R_{17}$, $-(CH_2)_kC(=O)NR_{16}R_{17}$, $-C(=O)O-R_{19}-NR_{16}NR_{17}$ and $-X_4-R_{18}$, in which :
 - X_3 represents a group selected from oxygen atom, sulphur atom and -NH group,
 - k is an integer from 0 to 3 inclusive,
 - R_{16} and R_{17} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
 - 20 - X_4 represents a group selected from single bond, $-CH_2-$, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
 - R_{18} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring, which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl, and
 - 25 amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
 - R_{19} represents a (C_1-C_6) alkylene group,
- optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

6- A compound according to claim 1 characterized in that:

W is C-R₁ and X is N or C-R₂ in which R₁ and R₂, identical or different, are selected from hydrogen and methyl,

Y is O,

5 Z represents an oxygen atom or a -NH group,

n is an integer from 0 to 4 inclusive,

Z₁ represents a group -CR₉R₁₀ wherein R₉ and R₁₀, identical or different, represent a group selected from hydrogen and methyl, and

- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one
- 10 double bond,
- and/or one of the carbon atoms in the hydrocarbon chain Z₁ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,

A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl,

15 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

m is an integer from 0 to 7 inclusive,

the group(s) R₄, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₅R₁₁, -OR₅, and -C(=O)OR₅, in which R₅ and R₁₁, which may be

20 identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

R₃ represents the group of formula:



- ✓ in which p is an integer from 0 to 4 inclusive,
- ✓ Z_2 represents $-CR_{14}R_{15}$ wherein R_{14} and R_{15} , identical or different, represent a group selected from hydrogen and methyl, and
 - when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one double bond,
 - and/or one of the carbon atoms in the hydrocarbon chain Z_2 may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C_1-C_6) alkyl,
- ✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothieryl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,
- ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) R_{13} , which may be identical or different, is (are) selected from (C_1-C_6) alkyl, halogen, -CN, $-CF_3$, $-NR_{16}R_{17}$, $-OR_{16}$, $-SO_2R_{16}$, $-(CH_2)_kSO_2NR_{16}R_{17}$, $-X_3(CH_2)_kC(=O)OR_{16}$, $-(CH_2)_kC(=O)OR_{16}$, $-X_3(CH_2)_kC(=O)NR_{16}R_{17}$, $-(CH_2)_kC(=O)NR_{16}R_{17}$, $-C(=O)O-R_{19}-NR_{16}NR_{17}$, and $-X_4-R_{18}$, in which :
 - X_3 represents a group selected from oxygen atom, sulphur atom and -NH group,
 - k is an integer from 0 to 3 inclusive,
 - R_{16} and R_{17} , which may be identical or different, are selected from hydrogen and (C_1-C_6) alkyl,
 - X_4 represents a group selected from single bond, $-CH_2-$, oxygen atom, and sulphur atom optionally substituted by one or two oxygen atoms,
 - R_{18} represents an aromatic or non-aromatic, heterocyclic or non-heterocyclic, 5- or 6-membered ring, which is optionally substituted by one or more groups, which may be identical or different, selected from (C_1-C_6) alkyl, halogen, hydroxyl, and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,
 - R_{19} represents a (C_1-C_6) alkylene group,

optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

7- A compound according to claim 1 characterized in that:

W is C-R₁ and X is N or C-R₂ in which R₁ and R₂, identical or different, are selected from
5 hydrogen and methyl,

Y is O,

Z represents an oxygen atom or a -NH group,

n is an integer from 0 to 4 inclusive,

Z₁ represents a methylen group, and

- 10
- when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one double bond,
 - and/or one of the carbon atoms in the hydrocarbon chain Z₁ may be replaced with an oxygen atom, a sulphur atom which is optionally substituted by one or two oxygen atoms, or a nitrogen atom which is optionally substituted by (C₁-C₆)alkyl,

15 A represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,

m is an integer from 0 to 7 inclusive,

20 the group(s) R₄, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₅R₁₁, -OR₅, and -C(=O)OR₅, in which R₅ and R₁₁, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,

R₃ represents the group of formula:



- ✓ in which p is an integer from 0 to 4 inclusive,
- ✓ Z₂ represents -CR₁₄R₁₅ wherein R₁₄ and R₁₅, identical or different, represent a group selected from hydrogen and methyl, and when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one double bond,
- ✓ B represents a group selected from phenyl, pyridyl, thienyl, imidazolyl, furyl, 1,3-benzodioxolyl, benzodioxinyl, benzothienyl, benzofuryl, 2,1,3-benzothiadiazolyl, benzofurazanyl, and indolyl,
- ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) R₁₃, which may be identical or different, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, -CF₃, -NR₁₆R₁₇, -OR₁₆, -SO₂R₁₆, -(CH₂)_kSO₂NR₁₆R₁₇, -O(CH₂)_kC(=O)OR₁₆, -(CH₂)_kC(=O)OR₁₆, -O(CH₂)_kC(=O)NR₁₆R₁₇, -(CH₂)_kC(=O)NR₁₆R₁₇, and -C(=O)O-R₁₉-NR₁₆NR₁₇ in which :
 - k is an integer from 0 to 3 inclusive,
 - R₁₆ and R₁₇, which may be identical or different, are selected from hydrogen and (C₁-C₆)alkyl,
 - R₁₉ represents a (C₁-C₆)alkylene group
 optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.
- 8- A compound according to claim 1 wherein n is equal to one, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.
- 9- A compound according to claim 1 wherein Z₁ represents a group -CR₉R₁₀ in which R₉ and R₁₀ represent each a hydrogen atom, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its the pharmaceutically acceptable salts thereof.

10- A compound according to claim 1 wherein A represents a 5- to 6- membered aromatic monocycle or a 3,4-methylenedioxyphenyl group optionally substituted by one or more groups R_4 as defined in the compound of formula (I), optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

5 11- A compound according to claim 10 wherein A represents a phenyl group optionally substituted by one group R_4 as defined in the compound of the formula (I), optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

10 12- A compound according to claim 11 wherein A represents a phenyl group, m is equal to one, and R_4 represents a methoxy group or a fluoro group, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

13- A compound according to claim 10 wherein A represents a 4-pyridinyl group and m is equal to zero, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

15 14 - A compound according to claim 1 wherein Z represents a -NH group and Y represents an oxygen atom, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

20 15 - A compound according to claim 1 wherein W represents a -CH group and X represents a nitrogen atom, optionally, its racemic forms, isomers thereof, N-oxydes thereof, and its pharmaceutically acceptable salts thereof.

16- A compound according to claim 1 wherein R_3 represent a group of formula :



in which p is equal to one, Z_2 represents a methylene group, B represents a phenyl group , q is comprise between 0 to 1 inclusive, R_{13} represents a group selected from -CN,

$-(CH_2)_k-C(=O)OR_{16}$, $-(CH_2)_k-C(=O)NR_{16}R_{17}$, and $-C(=O)-R_{19}-NR_{16}NR_{17}$ in which k , R_{16} , R_{17} , and R_{19} are as defined in the compound of formula (I), optionally, its racemic forms, isomers thereof, N-oxides thereof, and its pharmaceutically acceptable salts thereof.

17- A compound according to claim 1 selected from:

- 5 - benzyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
- 4-pyridylmethyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
- *N*-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide,
- *N*-(4-pyridylmethyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide,
- 10 - *N*-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide,
- *N*-(4-pyridylmethyl)-4-benzyl-5-oxo-4*H*-imidazo[1,2-*a*]quinazol-7-ylcarboxamide,
- *N*-(4-methoxybenzyl)-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxamide,
- 15 - *N*-[3-(4-pyridylsulphanyl)propyl]-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo-[4,3-*a*]quinazoline-7-carboxamide,
- *N*-(3,4-Methylenedioxybenzyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide
- 20 - Methyl 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate
- Methyl 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate
- Methyl 4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoate
- 25 - (2-Dimethylamino-ethyl) 4-[7-(4-fluoro-benzylcarbamoyl)-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl] benzoate
- 4-(4-Dimethylcarbamoyl-benzyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxylic acid 4-methoxy-benzylamide
- 30 - *N*-(pyridin-4ylmethyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide

- Methyl (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate
- Methyl (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate
- 5 - Methyl (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate
- *N*-(pyridin-4-ylmethyl) 4-[3-(pyridin-4-yl)-2-propen-1-yl]-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide
- 4-[2-(4-Chloro-phenoxy)-ethyl]-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxylic acid 4-methoxy-benzylamide
- 10 - 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid
- 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid
- 15 - 4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid
- 4-{7-[(4-fluoro)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl} benzoic acid
- (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid
- 20 - (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid, and
- (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetic acid.
- 25 18- A compound according to claim 1 selected from :
benzyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
4-pyridylmethyl 4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxylate,
N-(3,4-methylenedioxybenzyl)-4-benzyl-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]quinazol-7-ylcarboxamide,
- 30 *N*-(4-methoxybenzyl)-4-benzyl-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-*a*]quinazoline-7-carboxamide,

N-(3,4-Methylenedioxybenzyl)-4-(4-cyanobenzyl)-5-oxo-4*H*-[1,2,4]triazolo[4,3-*a*]
quinazol-7-ylcarboxamide

Methyl 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]
quinazol-4-ylmethyl} benzoate

5 Methyl 4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*] quinazol-4-
ylmethyl} benzoate

4-(4-Dimethylcarbamoyl-benzyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-*a*]quinazoline-7-
carboxylic acid 4-methoxy-benzylamide

10 Methyl (4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo
[4,3-*a*]quinazolin-4-ylmethyl}-phenyl)-acetate

Methyl (4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*] quinazolin-
4-ylmethyl}-phenyl)-acetate

4-{7-[(4-methoxybenzyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-
ylmethyl} benzoic acid

15 4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-
4-ylmethyl} benzoic acid

4-{7-[(pyridin-4-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-
ylmethyl} benzoic acid

20 4-{7-[(4-fluoro)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazol-4-ylmethyl}
benzoic acid


(4-{7-[(4-methoxy)-benzylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-
ylmethyl}-phenyl)-acetic acid

(4-{7-[(1,3-benzodioxol-5-ylmethyl)-carbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]
quinazolin-4-ylmethyl}-phenyl)-acetic acid, and


25 (4-{7-[(pyridin-4-yl)-methylcarbamoyl]-5-oxo-5*H*-[1,2,4]triazolo[4,3-*a*]quinazolin-4-
ylmethyl}-phenyl)-acetic acid.

19. Process for manufacturing a compound of general formula (I)

82




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is O and Z is O, the said process being characterized in that it comprises the reaction of the compound of formula (7a):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7g), in the presence of a base:



in which hal is a halogen atom, and in which R₄, n, m, Z₁ and A are as in the compound of formula (I),
to give the compound of general formula (7c), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.


15

20. Process for manufacturing a compound of general formula (I)

83




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is O and Z is -NR₈, in which R₈ is as defined in claim 1, the said process being characterized in that it comprises the reaction of the compound of formula (7a):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7i) :



in which R₄, R₈, n, m, Z₁ and A are as defined in the compound of formula (I),


10 by activating the acid function with an activator, in the presence of diisopropylethylamine (DIPEA) and in a solvent, to give the compound of general formula (7d), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.

15 21 - Process for manufacturing a compound of general formula (I),

84




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is O and Z is S, the said process being characterized in that it comprises the reaction of the compound of formula (7a):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7j):




in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),
 10 by activating the acid function with an activator, in the presence of DIPEA in a solvent, to give the compound of general formula (7e), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

15 22 -. Process for manufacturing a compound of general formula (I),

85




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is O and Z is O, the said process being characterized in that it comprises the reaction of the compound of formula (7b):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of formula (7h):




in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),
 10 in the presence of a base, to give the compound of general formula (7c), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

23 -. Process for manufacturing a compound of general formula (I),

86




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is O and Z is -NR₈, in which R₈ is as defined in claim 1, the said process being characterized in that it comprises the reaction of the compound of formula (7b):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of formula (7i):



in which R₄, R₈, n, m, Z₁ and A are as defined in the compound of formula (I),


10 in the presence of a base, to give the compound of general formula (7d), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.

24 -. Process for manufacturing a compound of general formula (I),

87




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is S, the said process being characterized in that it comprises the reaction of the compound of formula (7b):




5

in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7j):



in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),


10 to give the compound of general formula (7e), which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.


25 -. Process for manufacturing a compound of general formula (I),

88




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined above, Y is O and Z is -CHRa, in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, the said process being

5 characterized in that it comprises the reaction of the compound of formula (7b):




in which W, X, and R₃ are as defined in the compound of formula (I), with the compound of general formula (7k):



10 in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, Hal represents a halogen atom, and R₄, n, m, Z₁ and A are as defined in the compound of formula (I),


to give the compound of general formula (7f), which is a particular case of the compounds

15 of formula (I):




in which W, X, R₃, R₄, Ra, n, m, Z₁ and A are as defined hereinbefore.


26 -. Process for manufacturing a compound of general formula (I),



in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined in claim 1, and Y is S, the said process being characterized in that it comprises the reaction of the compound (8a):




in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined in the compound of formula (I), with Lawesson's reagent or P₂S₅, to give the compound of general formula (8b), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z, Z₁ and A are as defined hereinbefore.

27 -. Process for manufacturing a compound of general formula (I),




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Y is NH and Z is O, the said process being characterized in that it comprises the reaction of compound (9a):

90




in which W, X, and R₃ are as defined in the compound of formula (I),
with the compound of general formula (7h):




5 in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),

to give the compound of general formula (9b), which is a particular case of the compounds of formula (I):




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.

10 28 -. Process for manufacturing a compound of general formula (I),




in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Z is -NR₈ and Y is NH,
the said process being characterized in that it comprises the reaction of compound (9a):


91



in which W, X, and R₃ are as defined in the compound of formula (I),
with the compound of general formula (7i):




- 5 in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),
to give the compound of general formula (9c), which is a particular case of the compounds
of formula (I):




in which W, X, R₃, R₄, R₈, n, m, Z₁ and A are as defined hereinbefore.


- 10 29 -. Process for manufacturing a compound of general formula (I),



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Z is S and Y is NH, the
said process being characterized in that it comprises the reaction of compound (9a):




in which W, X, and R₃ are as defined in the compound of formula (I),
with the compound of general formula (7j):




in which R₄, n, m, Z₁ and A are as defined in the compound of formula (I),

- 5 to give the compound of general formula (9d) which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined hereinbefore.


30 -. Process for manufacturing a compound of general formula (I),



10


in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in claim 1, Z is -CHRa in which Ra represents a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, aromatic heterocycle, non-aromatic heterocycle, and cycloalkyl, and Y is N-Rb in which Rb is a (C₁-C₆)alkyl, the said process being characterized in that it comprises the reaction of

15 compound (7f):



in which W, X, R₃, R₄, n, m, Z₁ and A are as defined in the compound of formula (I), and
in which R_a is as defined hereinbefore,

with R_b-NH₂, in which R_b represents a (C₁-C₆)alkyl group, in a presence of a dehydrating agent, to give the compound of general formula (10a), which is a particular case of the compounds of formula (I):



in which W, X, R₃, R₄, n, m, Z₁, R_a, R_b and A are as defined hereinbefore.

31.- Pharmaceutical composition comprising a compound according to any one of Claims 1 to 18 and a pharmaceutically acceptable excipient.

32 -. Use of a compound according to any one of Claims 1 to 18, for the preparation of a medicinal product intended for treating a disease or complaint involving therapy by inhibition of type-13 matrix metalloprotease.

33 -. Use of a compound according to any one of Claims 1 to 18, for the preparation of a medicinal product intended for treating arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related macular degeneration and cancer.

34 - Use according to Claim 33, characterized in that the disease is arthritis.

35 - Use according to Claim 33, characterized in that the disease is osteoarthritis.

36 -. Use according to Claim 33, characterized in that the disease is rheumatoid arthritis.

37 - A method for treating a disease or complaint involving a therapy by inhibition of MMP-13, the said method comprising the administration of an effective amount of a compound according to any one of Claims 1 to 18 to a patient.

5 38- A method for treating a disease according to Claim 37 characterized in that the disease or the complaint are selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease (COPD), age-related macular degeneration (ARMD) and cancers.

10 39- A method for treating a disease according to Claim 37 characterized in that the disease is arthritis.

40- A method for treating a disease according to Claim 37 characterized in that the disease is osteoarthritis.

41- A method for treating a disease according to Claim 37 characterized in that the disease is rheumatoid arthritis.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/01961

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D487/04 A61K31/519

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 66584 A (WARNER-LAMBERT COMPANY) 9 November 2000 (2000-11-09) claims 1-34	1-41
A	EP 0 217 748 A (CIBA-GEIGY AG) 8 April 1987 (1987-04-08) page 2	1-41
A	EP 0 076 199 A (ROUSSEL-UCLAF) 6 April 1983 (1983-04-06) the whole document	1-41
A	US 4 455 311 A (FRANK KIENZLE) 19 June 1984 (1984-06-19) the whole document	1-41

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

29 May 2002

Date of mailing of the international search report

07/06/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/01961

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0066584	A	09-11-2000	FR 2792938 A1	03-11-2000
			AU 4411500 A	17-11-2000
			BR 0010072 A	05-02-2002
			EP 1177195 A1	06-02-2002
			WO 0066584 A1	09-11-2000
			NO 20015235 A	21-12-2001
EP 217748	A	08-04-1987	AT 60771 T	15-02-1991
			CA 1288097 A1	27-08-1991
			DE 3677445 D1	14-03-1991
			DK 464386 A	31-03-1987
			EP 0217748 A2	08-04-1987
			ES 2002012 A6	01-07-1988
			FI 863904 A ,B,	31-03-1987
			FI 88036 B	15-12-1992
			GR 862456 A1	29-01-1987
			IE 58968 B	01-12-1993
			JP 62135475 A	18-06-1987
			PT 83453 A ,B	01-10-1986
			US 4831013 A	16-05-1989
EP 76199	A	06-04-1983	AT 24509 T	15-01-1987
			AU 554959 B2	11-09-1986
			AU 8862382 A	31-03-1983
			CA 1193597 A1	17-09-1985
			DE 3274860 D1	05-02-1987
			DK 420682 A ,B,	25-03-1983
			EP 0076199 A2	06-04-1983
			ES 515904 D0	16-10-1983
			ES 8400440 A1	16-01-1984
			FI 823278 A ,B,	25-03-1983
			GB 2108495 A ,B	18-05-1983
			GR 78044 A1	26-09-1984
			HU 186975 B	28-10-1985
			IE 53858 B1	29-03-1989
			IL 66835 A	31-05-1988
			JP 1657677 C	21-04-1992
			JP 3022389 B	26-03-1991
			JP 58065292 A	18-04-1983
			MX 155086 A	26-01-1988
			PT 75602 A ,B	01-10-1982
			US 4472400 A	18-09-1984
			ZA 8206891 A	26-10-1983
US 4455311	A	19-06-1984	AU 8752482 A	03-03-1983
			DK 349682 A	01-03-1983
			EP 0073060 A1	02-03-1983
			ES 515295 D0	01-06-1983
			ES 8306375 A1	16-08-1983
			FI 822785 A	01-03-1983
			HU 185109 B	28-12-1984
			MC 1478 A	17-06-1983
			NO 822918 A	01-03-1983
			NZ 201659 A	31-07-1984
			PH 19683 A	13-06-1986
			PT 75472 A	01-09-1982
			GR 77609 A1	25-09-1984
			JP 58046088 A	17-03-1983

Information on patient family members

PCI/EP 02/01961

Form PCT/ISA/210 (patent family annex) (July 1992)